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Abstract
Both frequentist and Bayesian approaches have been used to characterize population pharmacokinetics and pharmacodynamics(PK/PD) models. These methods focus on estimating the population parameters and assessing the association between the characteristics of
PK/PD and the subject covariates. In this work, we propose a Dirichlet process mixture
model to classify the patients based on their individualized pharmacokinetic and pharmacodynamic profiles. Then we can predict the new patients’ dose-response curves given
their concentration-time profiles. Additionally, we implement a modern Markov Chain
Monte Carlo algorithm for sampling inference of parameters. The detailed sampling procedures as well as the results are discussed in a simulation data and a real data example.
We also evaluate an approximate solution of a system of nonlinear differential equations
from Euler’s method and compare the results with a general numerical solver, ode from R
package, deSolve.
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Chapter 1
Introduction

The development of drugs is time-consuming and costly. DiMasi (2003, 2001) reports that
it takes about 10 − 15 years to develop one new medicine from the time it is discovered
to when it is available for treating patients. The average cost to research and develop
each successful drug is estimated to be $80 million to $1 billion. This amount of money
includes the cost of thousands of failed compounds. For every 5000 − 10, 000 compounds
that enter the research and development pipeline, only one receives approval. For many
years, the U.S. Food and Drug Administration (FDA) has encouraged the development of
computational modeling and simulation to improve the efficiency in developing safe and
effective drugs. Therefore the technological advances in different fields related to drug
development is largely demanding to optimise current drug development practices.
The drug development consists of a preclinical and clinical component. The preclinical
process includes all early research on a large number of different compounds tested in
animals to gather safety and efficacy information. The process takes approximately 3 − 6
years. By the end, the researchers hope to have a promising candidate drug test in people.
The clinical study component is divided into three phases. In phase I, the drug is tested
in healthy humans (20 − 80 participants) for physiological compatibility. The goal in this
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phase is to determine the drug’s most frequent side effects and, often, how the drug is
metabolized and excreted. In phase II, the drug’s therapeutic effects are investigated and
the goal is to obtain preliminary data on whether the drug works in human who present
a certain disease or condition. Phase II trials sometimes involve hundreds of patients. In
phase III, the drug is tested in a larger sample of the population. The researchers gather
more information about safety and drug efficacy. They try to further understand the drug
behavior from different groups of patients and dosing regimens.
Pharmacokinetic and pharmacodynamic properties of a drug are of utmost importance
in clinical trials. Simply stated, pharmacokinetics (PK) describes the time course of a drug
in the body, whereas pharmacodynamics (PD) describes the study of the pharmacological
effects of a drug. If we are able to better understand the relationship between PK and
PD, we can expect to improve our knowledge of the underlying background mechanisms,
and eventually optimize the dosing regimen of a treatment to develop a personalized drug
therapy.
In this work, we propose to use the clustering property of Bayesian nonparametric infinite mixture models to borrow strength in the estimation of a semi-mechanistic PK/PD
model. First, we establish a coherent probabilistic model which connects the individualized PK and PD model. Second, we classify the patients into several homogeneous groups
on the basis of PK and PD profiles. More importantly, we can predict a new patient’s PD
profile based on its PK profile. The classification, estimation and prediction are achieved
in a single model framework. We also review two traditional approaches for PK and PD
model, nonlinear mixed effect model and the simple Bayesian hierarchical model. The
estimation of the nonlinear mixed effect model depends on the likelihood function. The
second one has been used to incorporate prior information in the model fitting. We discuss
a modern Markov Chain Monte Carlo sampling algorithm for posterior inference in our
model. In the end, we evaluate our model in a simulation data and a published clinical

2

Chapter 1. Introduction

trial data. In the simulation data, we also use Euler’s method to linearize the system of
nonlinear ordinary differential equations (ODEs) and compare its results with a general
numerical ODE solver, ode, from an R package (deSolve).
The structure of the thesis is as follows. In chapter 2 we introduce PK and PD as
well as the models describing PK/PD process. Chapter 3 presents two existing statistical
approaches for fitting PK/PD models: nonlinear mixed effect models and Bayesian models. In chapter 4 we present the nonparametric Bayesian framework and discuss a modern
Markov chain Monte Carlo algorithm that we will use later. In chapter 5 we discuss our
proposed approach and provide a detailed MCMC sampling algorithm. The relevant results from the simulation data and a real data are also presented. In chapter 6 we present
the conclusions and discuss future research work.

3

Chapter 2
Population pharmacokinetic and
Pharmacodynamic (PK/PD) Models

The whole PK/PD modeling process includes careful data management (import, process,
visualization of the time-course data), development of a PK/PD model, estimation of parameters using statistical methods, prediction and extrapolation beyond the existing data.
Population pharmacokinetics studies the variability of plasma drug concentrations in a
certain population after a standard dosage administered (Aarons 1991). The aim of PK is
quantifying the variability within the population and accounting for it in terms of patient
covariates, such as age, sex, disease state. Population pharmacokinetics can identify the
measurable factors that cause changes in the dose-concentration relationship and the extent of these changes. It helps us better understand how these factors affect the absorption,
distribution and elimination of the drug.
Population pharmacokinetics and pharmacodynamics describes the relationship
between drug response and concentration of a drug and the variability of inter- and intrasubjects in a population. The population PK/PD models consist of two parts. The first

4

Chapter 2. Population pharmacokinetic and Pharmacodynamic (PK/PD) Models

part describes a population PK model and we can obtain the PK parameter estimates for
each individual. The second part is the corresponding PD model. There are primarily
two ways to perform the population PK/PD modeling: simultaneous and sequential. In
the simultaneous modeling, both PK an PD estimates are obtained at the same time. In
the sequential approach, PK parameters are estimated for each individual first and then
PD parameters are estimated based on PK information as a known covariate in the PD
modeling. In our approach, we use the simultaneous approach to estimate the PK and
PD parameters. In this chapter, we introduce the data-based non-compartmental model,
compartmental model and physiology-based model for PK, steady-state and non steadystate PD models.

2.1

Pharmacokinetic models

Pharmacokinetics studies how the body affects a specific drug over time. It attempts to
discover the fate of a drug from the moment that it is administered till it is completely
eliminated from the body. The whole process includes the mechanism of absorption, distribution as well as the chemical changes of the drug, i.e. metabolic enzymes. Absorption
is the process that involves drug movement from site of entry into bloodstream. After adminstration, a drug will be distributed itself into all of body’s compartments and tissues
that it is able to. The time it takes for this to occur is called distribution phase. Volume
of distribution can be estimated based on sampling blood concentration after dosing with
the assumption that the drug uniformly distributed throughout the body. Metabolism is the
process by which a drug is chemically inactivated, i.e. broken down by enzymes, so that
it can be excreted from the body. The excretion is the process that a drug is removed from
the site of action and eliminated from the body. After a dose of drug is administered, the
body begins to eliminate the drug by hepatic metabolism, renal excretion or both. The aim
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of PK modeling is to explain and characterize the variability of these processes based on
the observations over time. Next we review three different pharmacokinetic models, databased non-compartmental model, compartmental model and the physiology-based model.

2.1.1

Data-based non-compartmental models

The data-based non-compartmental model is the simplest approach to measure the drug
exposure and explain the variability across doses and subjects. The parameters include
maximum plasma concentration, Cmax , time to reach Cmax , Tmax , area under the plasma
concentration-time curve AUC which determines the drug exposure over a period of time,
total clearance CL which describes how quickly drugs are eliminated, metabolized or distributed throughout the body, total volume of distribution Vc etc. The non-compartmental
model is highly dependent on the estimation of the AUC, calculated by numerical integration e.g. a trapezoidal rule. If we have a smooth line for concentration versus time or
an equation for Ct from a pharmacokinetic model we could slice the area into vertical
segments. The total area AUC is the sum of all the segments. In calculus, the total area is
given by 2.1,
Z
AU C =

∞

Ct dt

(2.1)

0

The thinner the segments are, the closer the trapezoids reflect the actual shape of the
concentration-time curve. A sum of exponential terms are often used to describe the drug
concentration-time profiles as follows,
X
Ct = A ·
exp−λi t

(2.2)

where Ct , A, λi are drug concentration over time, coefficient constant and terminal rate
respectively (more explanations in 2.5 and 2.7).
In summary, the non-compartmental models are widely useful for data description and
interpolation, Gabrielsson (2012). They can also be used to show that two formulations are
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the same in the development of new drugs by calculating AU C and Cmax . For example, the
manufacturer may study the drug initially with capsules but may wish to market a tablet to
patients as the latter trend to have greater stability. To do so, the manufacturer has to show
that the two formulations are bio-equivalent which means that the two formulations have
the same concentration-time profile within an acceptable tolerance region. In this case,
calculate the Cmax and AU C under both formulations for n patients. Bio-equivalence is
declared if the confidence interval for the ratio of means of test/reference for both AU C
and Cmax are entirely within the interval (80%, 125%), US Food and Drug Administration, Bioavailability (2000). In addition, they are often implemented in physiologicallybased pharmacokinetics and pharmacodynamic models Gillespie (1991). However, they
are difficult to do extrapolation, Aarons (2005). Because their parameters do not have
the physiological interpretations. Thus it is difficult to predict how the concentration-time
profiles change when the underlying physiology changes. This problem can partly be
addressed by adopting the compartmental models.

2.1.2

Classical compartmental models

In order to obtain insight from a certain study, (e.g. biological systems), scientists divide
the objects of scientific interest into smaller conceptual units until the underlying mechanisms become apparent (a basic logic in science). This basic principle also works for
the pharmacological phenomena. A class of small conceptual units have been developed,
known as compartments. The organism where the drug goes is thought of as a system of
interconnected pools, compartments. In order to understand the whole mechanism, the researchers need to study the single compartment and the passage of the drug between them.
For simplicity, we will describe the one- and two-compartmental models and discuss advantages and limitations of using compartmental modeling approach.
One-compartmental model is assumed to comprise only a single compartment repres-
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(c)

Figure 2.1: Examples of one and two compartment models modified from Holz et al.
(2001) (a) Bolus/pill administration (b) First order absorption (c) Two compartment model

enting the systemic circulation. Figure 2.1.2 shows an one-compartmental model for a
single input pathway and single elimination pathway, a with bolus/pill administration and
b IV administration with first-order absorption. The uptake source and the place of elimination process are usually displayed as circles while the compartments of the organism are
symbolized by squares or rectangles. where kabs and keli are constants indicating the rate
of absorption and elimination respectively. The main interest is the drug concentration as
a function of the time after administration. The “into” and “out” flow of the process in the
compartment can be described mathematically. The ”into” process can be described by
dA(t)
= −kabs · A(t),
dt

(2.3)
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and the “out” process can be expressed by
dC(t)
= kabs · F · A(t) − keli · C(t),
dt

(2.4)

where A(t) is the amount of drug still remaining to be absorbed and F is the absolute
bio-availability (describing how much drug reaches the circulation system after administration, i.e. the bio-availability of an intravenous drug dose is assumed to be 100%).
The mathematical solution of the differential equations 2.3 and 2.4, with the initial value
A(0) = Dose and C(0) = 0 is
C(t) =


F · Dose · kabs −keli t
e
− e−kabs t ,
Vd · (kabs − keli )

(2.5)

where VD is the volume of circulation compartment. Given the values of Dose, VD , kabs ,
keli and F , the drug concentration in the blood over time can be easily obtained.
The two-compartmental models resolve the body into a central compartment and a
peripheral compartment (see Figure 2.1.2 (C)). They are assumed that the central compartment includes the tissues that are highly perfused such as blood, heart, lungs, liver,
kidneys and brain. The peripheral compartment comprises poor-perfused tissues such as
muscle, fat and skin. After drug administrated into the central compartment, the drug is
assumed to distribute between that compartment and the peripheral compartment. However, the drug does not achieve instantaneous distribution between the two compartments.
Here we present a simple two-compartmental model which is described as follows. The
system of ordinary differential equations is:
dC1 (t)
= −(k10 + k12 )C1 (t) + k21 C2 (t),
dt
dC2 (t)
= k12 C1 (t) − k21 C2 (t),
dt

(2.6)

where C1 and C2 represent the amount of drug in the central and peripheral compartment,
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respectively. The solution for bolus administration with C1 (0) = Dose and C2 (0) = 0 is
C(t) = A · e−α·t + B · e−β·t

F · Dose 
(α − k21 )e−αt + (k21 − β)e−βt )
=
VD (α − β)

(2.7)

with
α · β = k12 · k10

(2.8)

α + β = k12 + k21 + k10

(2.9)

and

where k10 , k12 , k21 are the elimination rates constant from compartment one, the intercompartmental flow rate respectively. With a simple algebra, these rate constants can be
solved easily.
The model becomes more complicate when we start considering multiple compartments in the system, such as catenary and mammillary compartmental structure see Figure
3 in Holz (2003). A mammillary model consists of a central compartment interacting with
a number of peripheral compartments surrounding it. The catenary model comprises of a
chain of interconnected compartments. The time course of the concentrations will always
follow a sum of exponentials under a certain assumption. However, it may need more
complex techniques to solve the equations.
Nowadays, the compartmental models are still widely used in various area. Kreuer
(2014) proposed a three-compartmental pharmacokinetic model extended with an additional lung compartmental and clearance to measure drug concentration in patient’s breath.
Yamazaki (2015) proposed a one-compartmental PK model to describe oral and subcutaneous profiles of anaplastic lymphoma kinase inhibitors.
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2.1.3

Physiologically-based Pharmacokinetics models (PBPK)

In the 1930s, Teorell (1937a, b) provided a set of equations for uptake, distribution, and
elimination of drugs from the body. These papers are regarded as providing the first
physiological model for drug distribution. However, computational methods were not
available to solve the sets of equations at that time. The focus shifted to the simple models
such as data-based non-compartmental and one- or two- compartmental models. Because
they have fewer number parameters and these parameters do not correspond directly with
a specific physiological compartment. For the next thirty years, PK modeling focused on
these simpler descriptions with exact solutions. However, with the availability of computers and numerical integration algorithms, it regains the interest in physiology-based
model from 1970s. By 2010, hundreds of publications used PBPK models and some companies’ business based on their expertise in PBPK. There is also a growing interest in
applying PBPK models for the discovery and development of drugs, Lupfert 2005.
PBPK models are compartmental models like the classical pharmacokinetics compartmental model, but the compartment here represents the actual tissue and organs. In general, the concept of PBPK is to use mathematical equations to describe relevant physiological, biochemical process which determines the pharmacokinetic behavior of a compound. PBPK model is structured to compose the relevant physiological compartments.
Each compartment often represents a single organ or tissue. These compartments are
interconnected via the blood circulation loop. The mass-balance equations for each compartment describe the rate of substance change within it.

11

Chapter 2. Population pharmacokinetic and Pharmacodynamic (PK/PD) Models

Figure 2.1.3 illustrates the generic stucture of building a PBPK model. It includes the
monitoring of the drug concentration in core tissue, fluid and organs (arterial and venous
blood), liver (the main metabolising organ), kidney (for renally excreted drugs). Within
each compartment, mathematical equations are derived from the law of mass transfer.
Linear or nonlinear differential equations are the most common description of the pharmacokinetic processes. The PBPK models have two groups of parameters: drug-specific
and physiological parameters. Typical drug-specific parameters include metabolism rate
and plasma protein binding constants. The physiological parameters include regional and
tissue blood flow rates, volumes of blood and different tissues parameters etc. An example
of a system of ordinary different equations are described for a real world problem Craigmill (2003). This model is to see how a chemical injected into a body of an animal spread
into all the organs and how the concentration of chemical changes over time in each organs. The diagram for the model is shown 2.1.3, with a complicate differential equations
followed 2.1.3. See more details and explantation in the original paper.
The PBPK modeling has attracted considerable attention in pharmacological and toxicological research (Grass and Sinko, 2002). There are also more applications in the dose
estimation (Johnson 2005) and drug-drug interactions (Chien, Monhutsky et al. 2003).
Another important area of PBPK application is the drug discovery and development in
Lupfert and Reichel (2005), Latz (2009). Jones and Rowland-Yeo (2013) presents a comprehensive tutorial for PBPK. Huang and Rowland (2012) discussed the role of PBPK
modeling in regulatory review. We refer the interested reader for PBPK models to Reddy
(2005).
In summary, the use of PBPK modeling to maximize the clinical potential of drugs
has been accepted in pharmacokinetics. But it requires intense resources to generate
the data on the various parameters in the model. The mathematical complexity of the
model and computationally intensive limit the application of PBPK modeling. Therefore,
user-friendly software would enhance the widespread use as well as the knowledge of
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physiology and biochemical process, especially in different disease states.

2.2

Pharmacodynamic models

Pharmacodynamics (PD) refers to the relationship between drug concentration at the site
of action and the resulting effect, including the intensity of therapeutic and adverse effects.
The magnitude of a drug response at the action site is determined by the amount of drug
binding to a certain type of receptor. More drug is at the action site, the stronger intensity
of a drug’s effect is. PD model quantifies the relationship between dose and response.
There are two basic assumptions in PD models. The first one is that the measured plasma
concentration is proportionally related to the concentration at the effect site. Ideally, the
concentrations should be measured at the effect site, the action site or biophase where the
interaction with the corresponding receptor system occurs, but this is not possible for most
drugs. However, the concentrations could be easily accessed in body fluids like plasma or
blood. The plasma concentrations are frequently used to establish the relationship between
a dose of drug and response.
The second assumption is about the drug effect. The drug effect can be defined as any
drug-induced change in a physiological parameter when compared to the baseline value.
The baseline is the values of the same physiological parameters in the absence of drug
dosing. Baseline values do not necessarily have to be constant but can change, i.e. as a
function of day. Moreover, “effect” has to be clearly separated from “efficacy”. Efficacy
is the sum of all therapeutically beneficial drug effects and is the most relevant target
parameter in clinical trial. In practice, efficacy is difficult to quantify and thus instead
use the easily accessible surrogate markers as effect parameters. But it needs to present
evidence that the effect parameters used correlates with the desired efficacy. In practice,
the measured response could be both continuous and categorical, i.e. blood pressure,
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cure/not cure,none, mild moderate and severe. In those cases logistic regression models
and survival analysis are applied to describe the probability of the events. The relationship
between concentration and the logit of the probability of the event is typically modeled as
a linear or Emax function. For a dichotomous longitudinal variable the probability of an
outcome P (t) may be estimated based on
L(t) = E0 + Slope × C(t)

P (t) =

expL(t)
1 + expL(t)

(2.10)

where L(t) and E0 are the total and underlying effects on the logistic scale. In this section
we introduce the PD models in steady-state and non steady-state conditions.

2.2.1

Pharmacodynamic models for steady-state situations

When the concentration of the agent at the action site are constant and the PD parameters
are time-invariant, the system is said to be kinetically at steady state. The steady-state
condition can be reached with long-term IV infusions or multiple-dose regimens. Several
basic PK/PD models have been used to describe concentration-effect relationship, such as
fixed effect model, linear model, log-linear model, sigmoid Emax model Meibohm (1997).
The frequently used one is the sigmoidal Emax model, Mager (2003),
E(t) =

Emax × C(t)r
+ E0
r
EC50
+ C(t)r

(2.11)

where Emax is the maximum effect that can be achieved by the drug in the investigated system and EC50 is the drug concentration that results in half of the maximum effect. EC50
is inversely related to the potency. γ is the sigmoidicity factor that determine the steepness
of the relationship but is in many cases not statistically significant from 1. Among effect
and log-concentration relationship,

• If r = 1, it is for a hyperbolic curve.

14

Chapter 2. Population pharmacokinetic and Pharmacodynamic (PK/PD) Models
• If r > 1, the relationship becomes steeper and will eventually approach a stepfunction.
• If r < 1, it is for a smoother curve.
One reason for the popularity of the Emax model is that the function asymptotes to an
upper limit of stimulation or inhibition by a drug on a system. However, often there are
situations when sufficienty high concentrations can not be achieved to estimate Emax and
simplification can be made where fewer parameters are estimated. When the concentrations are much smaller than E50 , the Emax model collapses to a linear model (γ = 1) or a
power function with coefficient Slope as shown in 2.12,
E(t) = E0 + Slope × C(t)γ

(2.12)

Another issue is that the underlying E0 is not always constant over the drug period. For
example, the effect variable may vary because of an underlying disease, such as fluctuations in glucose in the event of diabetes in blood pressure. The model complexity can
increase with increased availability of data and knowledge of the underlying system. For
example, there may be feedback mechanisms that regulate the measured variable, such as
the influence of insulin on glucose levels. In addition, after drug administration, the drug
effect delay are frequently observed. There are multiple issue to affect the delay, such as
slow distribution to the effect site, active metabolite formation, signal transduction and
other mechanisms.

2.2.2

Pharmacodynamic models for non-steady-state situations

Under non-steady-state conditions, the time course of plasma concentration and effect
dissociate. Thus, to fully characterize the time course of drug action, PK and PD have to
be adequately linked to predict the relationship of PD effect versus plasma concentration.
Next we review two basic attributes in the integrated PK/PD models.
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Direct Link vs. Indirect Link
If drug concentration in plasma occurs rapidly enough at the effect site, which means the
temporal delay negligible, the concentrations are directly proportional in between over
time. The effect and plasma concentration lack any detectable hysteresis and may be directly linked. However, in many cases, the concentration at the site of action may lag
behind that in plasma; then no direct link can be established. This is usually manifested
by a hysteresis between plasma concentration and effect. See an example in Suri et al.
(1997). The extent of hysteresis is dependent on the degree of delay between the concentrations in plasma and at the effect site. This can be resolved by introducing a hypothetical
effect compartment representing active drug concentration at the effect site. Linking the
effect compartment to the kinetic model with negligible mass of drug into the effect compartment.

Time Variant vs. Time Invariant
In PD model, most parameters are assumed to time invariant, i.e. Emax and EC50 stay
constant over time. However, when time-variant PD occurs, a specific model for the involved process of tolerance is required. The tolerance is defined as a decrease in drug
effect over time, despite constant drug concentrations at the effect site, and is characterized by a clockwise hysteresis loop in a plot of effect versus drug concentration. In an
Emax model, tolerance is usually modeled as a time-dependent decrease of EC50 if receptor desensitization is assumed.
In summary, under non-steady and steady-state, there are several pharmacodynamic
models have been used to describe the relationship between drug concentration and effect.
The preferred models depend on many factors, including 1) the type of the drug used 2) the
response to be measured, 3) the effect seen after administration of drug, 4) the linearity in
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the effect-concentration curve, 5) the characteristics of parameters whether represent the
underlying process and mechanism.

2.3

Population PK/PD Models

The population approach is often employed to indicate a paradigm that attempts to define
important PK and PD differences and extract this information from complex data. The
ultimate goal of PK/PD analysis is to establish guidelines for individualizing dosage regimen. It consists of quantifying the mean and variance of PK/PD population parameters as
well as the intra- and inter- subject variability. In addition, it is also possible to investigate
the factors or covariates, such as age, weight, gender, which may help to distinguish the
difference among individuals or subgroups of the population.

2.3.1

Mechanism-Based PK/PD models

The PK data analysis is often considered routine and straightforward, but major physiological insights have derived from basic physiology principles. The time course of drug
concentrations in a relevant biological fluid, i.e. unbound plasma concentration, Cp , are
typically represented by a mathematical function:
Cp (t) = f (θP K , Dose, t)

(2.13)

where θP K is a vector of PK parameters determined by model fitting, Dose represents the
amount of medicine, t is the time course.
If plasma concentrations are assumed to be proportional to biophase concentrations,
then these expressions are served as known information in PD models.
E(t) = f (θP D , Cp , t, X)

(2.14)
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where E(t) is the pharmacological response over time and X represents a vector of drugindependent system parameters, i.e. age. Both equations 2.13 and 2.14 may be explicit
for some simple systems. In general, the population PK/PD approach imposes the distributional assumption on the individual-specific PK and PD parameter vectors, θP K and
θP D .
θi,P K ∼ N (µpk , Σpk )

θi,P D ∼ N (µpd , Σpd )

(2.15)

where N (·, ·) denotes a p-dimensional multivariate normal distribution with mean and covariance matrix. The main interest is to use the concentrations as a primary predictor to
construct a realistic model for drug effect that allow the efficacy and various covariates
to be explored. Nielsen and Friberg (2013) promoted more extensive use of modeling
and simulation to describe time courses of antibiotic drug effects in animals and patients.
Their review summarize the value of PK/PD modeling and provided an overview of the
characteristics of available PK/PD models of antibiotics. Dong (2014) developed a population PK/PD model for mycophenolic acid in paediatric renal translate recipients. They
used a two compartmental model with a transit compartment for PK modeling. For the
PD model, a non-linear relationship between dose and acid exposure was described by a
power function.
The objective of a PK/PD modeling is not just to describe the data sets of the sample
of individuals but also used to simulate which concentration and effect and evaluate the
variability of drug response for the future patients when different doses are given. These
simulation and prediction can lead to optimised dosing recommendation. It is often said
that “all models are wrong but some are useful”. In order to define whether a population
PK/PD model is useful and valid in clinical study. A number of evaluation and validation
models have been performed such as goodness-of-fit models, bootstrap analysis, visual
predictive evaluation. Cock (2010) reviewed a few validation models of PK/PD modeling in paediatric clinical research. Burns (2014) proposed a population PK/PD model of
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caffeine by using visual analogue scale and evaluated both simultaneous and sequential
PK/PD modeling. Model validation were performed using diagnostic plots and visual predictive check plots.
The “mean” functions in population PK/PD models are often expressed by a system
of differential equations describing the kinetic and dynamic process in the body. Most
often, the analytic solutions of these equations do not exist. However, there are several
numerical solvers available, such as Runge-Kutta methods, adams methods and backward
differentiation formula. The choice of these approaches is on the base of the characteristics of the systems, i.e. stiffness. An ODE system is called stiff if the state variables
change on a wide variety of time scales, including changing very rapidly as well as changing very slowly. Solving “stif” ODEs may request the special methods. An excessive
amount of computing time is required because it takes time to use very small time steps to
maintain stability. In addition, solving a system of ODEs depends on the “good” choice
of the starting values of parameters. The common packages of ODE solvers are available
in the programming languages i.e. FORTRAN (ODEPACK solver), C (CVODE solver),
MATLAB (ode45/ode15s solver) and R (deSolve package). In our work, we use R package, deSolve for solving PK and PD ODEs and also implement a self-written R code of
Euler’s method for PD ODEs.

2.3.2

Overview of softwares of population PK/PD modeling

There are various softwares available for PK, PBPK and PBPKPD modeling in drug development processes. They are Phoenix WinNonlin, P-PHARM, PHEDSIM, MEDICIPK, Modkine, PDx-MC-PEM and JGuiB. These are well user friendly software for not
only simple PK/PD model but also for population PK/PD models. WinNonlin is popular because it includes extensive libraries for PK and/or PD and PK/PD models and it
also provides tools for table generation, scripting and data management. Roccheti (2009)
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provided a PK/PD analysis for estimating PK/PD parameters and computing the expected
tumor growth curves was carried out by WinNonlin V.3.1.
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Figure 2.2: A generic structure of the whole-body PBPK-model Dickschen (2012). The
model organism is built by compartments, each typically representing a single organ
defined by its physiological volume. Organs are interconnected via respective blood flows
which occur, except for pulmonary circulation, from the arterial blood pool to the venous blood pool thus accounting for inter-compartmental mass-transfer. Application of
substances can be defined as intravenous (i.v.), per oral (p.o.), or into any desired compartment. In addition to clearance events in intestinal wall, liver, and kidney, metabolism
processes can be implemented into any compartment. Transport processes that significantly influence a compounds PK may be inserted between compartments.
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Figure 2.3: A diagram of PBPK model structure Craigmill (2003).

Figure 2.4: An example of a system of differential equation for each compartment Craigmill (2003).
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Chapter 3
Literature review on statistical
approaches for population PK/PD
models

In the field of biomedical applications, data usually consists of repeated measurements
on individuals under varying experimental conditions. For example, in pharmacokinetic
studies several blood samples are taken on participants over a period of time following the
administration of a drug. Those participants can be considered as a random sample from
a population of interest. The measured response is often not nonlinear with the varying
experimental condition with the parameters. The model is fitted to data sets from different
individuals. The main interest is to obtain inference on both population and individual
characteristics, and their variability.
Two common approaches are considered to fit the population PK/PD data. The first approach is to fit all data sets simultaneously in one simple model (simultaneous method). In
other words, PK and PD parameters are estimated at the same time. The second approach
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is to fit a model for the PK data first, then model the PD outcome conditional on the PK
data and/or estimates (“sequential” method). Zhang et al. (2003) uses the simulation data
to compare the performance of a simultaneous method with the sequential method. They
validated the results with respect to computation time, estimation precision and inference.
In the end, they concluded that the computation time of the sequential method is less and
the estimates are more easily obtained. Thus in our work, we fit both PK and PD data
simultaneously in our MCMC algorithm.
PK/PD have a precise administration in clinical trial study. The patients often receive
different doses of drug. Blood samples are collected over a period of time. In our real
data, paclitaxel was administered as a 3-hour infusion, with initial dose of 175mg/m2
every 3rd week. Dose adjustments were guided by hematological and nonhematological
toxicity which resulted in a final dose range of 110 to 232 mg/m2 . Plasma concentrations
were monitored on course 1 and course 3, with an average of 3.5 samples per patient and
course.
There are several statistical methodologies to model the population PK/PD data. The
simplest approach is called “naive-pooled dat”. The “naive-pooled data” approach is to
fit all individuals’ data together without considering inter- and intra- subject variability.
The “two-stage” approach fits each individual’s data separately and then combines the individual parameter estimates. In the first stage, each individual PK/PD parameters are estimated from the individual PK and PD observations. In the second stage, the relationship
between covariates and the parameters are explored. The population mean and variance of
each parameter is derived. The third approach is the nonlinear mixed models. Nonlinear
mixed models is a mixture of fixed and random effects. Fixed effect is often repeatable
and the experimenter can directly manipulates. Random effect is the source of random
variation. The fixed effects estimate the population coefficients but the random effects account for the individual difference in response. The fourth approach is Bayesian. which
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incorporates the initial belief for the parameters in the model. Historically, the difficulty of
implementing the Bayesian analyses in complex statistical models was the intractability of
the numerous integrations. However, vigorous development of Markov chain Monte Carlo
(MCMC) techniques facilitated such integration in the early 1990s. Additionally new advances in computing power have made such Bayesian analysis feasible. The nonlinear
mixed model served as one of the first examples of this capability (Rosner and Muller
1994). We will provide a brief review of the important features of Bayesian inference. See
Davidian and Giltinan (1995, Ch.8) for an introduction and Carlin and Louis (2000) for
comprehensive coverage of modern Bayesian analysis. In this chapter, we review last two
approaches for the PK/PD models. In section 3.1, we review nonlinear mixed-effect models with available programs. In section 3.2, we discuss the Bayesian models and available
software.

3.1

Statistical Inference for Nonlinear Mixed-effect Models

Within the framework of nonlinear models, the main interest is focused on representing
the mean function, or mean trajectory, describing the dynamic relationship between the
response and explanatory variables, i.e. time. Most often, the means functions are described by a system of ordinary differential equations (ODEs). (We skip ODEs for now
and discuss it more at the end of this chapter.)
The nonlinear mixed-effect model is the traditional approach for longitudinal data. The
concept of nonlinear mixed-effect model (NLMEM) first appeared in (Sheiner, Rosenberg,
Melmon 1972), modeling of individual PK for computer aided drug dosage. In 1977, the
first case study used NLMEM shown up in Sheiner, Rosenberg Melmon. They estimated
the population characteristics of PK parameters from routine clinical data. In late 1980s,
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it was widely spread in statistical research. There are numerous new methodologies and
computational techniques developed for these models in late 1990s, like NONMEN software (an IBM-specific software). The estimation methods for population parameters are
the First Order method, Laplace approximation, and First Order linearization etc. Sheiner
and Beal published three important papers and evaluated the methods for estimating population pharmacokinetic parameters. From 1985 to 1990, nonparametric, bayesian estimation of individual random effects given current estimates appeared, such as linearisation
of the model around the current estimates of the random effect, Newton-Raphson iterative
solution to a linear mixed effect estimation problem (Lindstrom and Bates (1990)).
Here we first introduce a simple version of nonlinear mixed-effect models and then
review several inferential methods. Let yij denote the jth observed response, for ith subject, measured at time point tij , for i = 1, 2, · · · , m and j = 1, 2, · · · , ni . For example,
in pharmacodynamic settings, yij is the absolute neutrophil count at time tij for subject
i. The following methodology we present can be extended to a more general case with
multiple covariates. A statistical model can be expressed as,
yij = f (θ i , tij ) + ij ,

i = 1, . . . , m,

j = 1, . . . , ni

(3.1)

For an individual i, the intra-individual error ij corresponds to the measurement uncertainty associated with the observed response at time point tij . The random errors are
assumed to be independently distributed with zero mean and constant variance across all
measurements,
E(ij ) = 0

and V ar(ij ) = σ 2

for

i = 1, 2, · · · , m and

j = 1, 2, · · · , ni (3.2)

For simplicity, errors are assumed to be i.i.d, identically independent distributed. Although this assumption is very strong, it can be relaxed to the case that the variance of
errors to be, V ar(i ) = σi2 Ri , where i = (i1 , · · · , ini ), Ri is a ni × ni positive definite
matrix. Ri may depend on other parameters. For simplicity, we consider Ri as an identity
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matrix with the number of ni elements. In equation 3.1, f (·) is the mean function describing the within-individual behavior. It depends on a vector of p parameters, θ i , specific to
individual i. θ i s are assumed to from a common distribution with mean θ and variance
Σθ . Specifically we can write,
θ i = d(θ, bi ),

bi ∼ N (0, D)

(3.3)

3.3 represents the individual behavior conditional on θ i and hence on bi , the random component in 3.3. In 3.3, we assume that the distribution of bi |X i does not depend on all
the covariates X i . All bi ’s have a common multivariate normal distribution with mean
0 and covariance D. In our real data, the PK parameter vector θ i is (CLi , Vic , Vid , CLdi )
representing the system clearance, volume of central compartment, volume of peripheral
compartment, clearance of inter-compartment separately.
The joint density of the observed data y 1 , · · · , y m is,
ni
m Z
m Z Y
Y
Y
p(y i , bi |θ)dbi =
p(y ij |bi , θ)p(bi )dbi
i=1

i=1

(3.4)

j=1

Ideally, the parameters involved in the NLME model can be estimated by maximizing the
joint density of all parameters based on equation 3.4. If f is a linear function of parameter
θi , the integral can be evaluated to obtain an analytic expression. Here we present a
very simple example where the joint density of parameters can be formalized. We do not
consider any covariates for now and set
θ i = θ + bi ,

E(bi ) = 0,

V ar(bi ) = D

(3.5)

The likelihood function assuming normality of the responses and random effects can be
written as,
ni
m Z Y
Y
1
1 − 12 (yij −f (θi ,tij ))2
−1
T
L(θ, D, σ) ∝
e 2σ
|D|−1/2 e− 2 (θi −θ) D (θi −θ) dθ i
D
i=1
j=1
Z
m
Y
1 P ni
−1
2 1
T
1 ni /2
−1/2
=
( 2 ) |D|
e− 2σ2 j=1 (yij −f (θi ,tij )) − 2 (θi −θ) D (θi −θ) dθ i
σ
i=1
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Even though the likelihood in 3.6 has a specific form. However, in most cases of NLME
models, f is a nonlinear function of parameters θ i . Nonlinearity means that the m integration in equations 3.4 and 3.6 can not be solved in a closed form. Thus, it is not
possible to obtain the analytic solution. In practice, the classical approaches are based
on approximation of the likelihood involving the linearization of the nonlinear model by
using either Taylor’s series expansion (Beal and Sheiner (1982)) or by applying Laplace’s
approximation to the likelihood (Wolfinger, 1993). Then estimate the parameters based on
the approximated likelihood functions. Here we review several methods based on approximation of the likelihood according to the equations from 3.1 to 3.3.

3.1.1

Exact method

By exact methods, we mean methods which avoid approximations, such as exact maximum likelihood estimation (MLEs) or Bayes estimation. In order to obtain MLEs or
bayesian estimate, one must evaluate a high dimensional integral which requires numerical methods, i.e. Monte Carlo. For MLE, the marginal density of yi given the parameters
bi , θ is required,
Z
p(yi |θ, bi ) =

p(yi |θ, bi )p(bi )dbi

(3.7)

In most cases, f is nonlinear in the random effect bi . So there is no closed form expression
for this integral. Both Calculating MLEs or Bayesian estimates can be computationally
difficult and time consuming especially when bi is more than one-dimensional. Next we
use the simplest model to introduce several approaches to approximate the function f .
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3.1.2

First order methods

This method, developed by Beal and Sheiner (1982), is extensively used in pharmacokinetics. First order method is based on using a Taylor expansion to approximate the model
function f , and maximizing the likelihood corresponding to the resulting approximation.
The first-order Taylor expansion of fi (·, bi ) around bi = 0 gives the approximate model
yi = fi (θi , tij ) + i ≈ fi (·, bi = 0) + fi0 (·, bi = 0)bi + i

(3.8)

where fi0 (·, 0) is the derivative of fi (·, ·) with respect to bi evaluated at bi = 0. We can
write down the approximate marginal distribution of yi which is normal with expection
fi (·, 0) and variance σ 2 Ini + fi0 (·, bi = 0)D[fi0 (·, bi = 0)]T . Maximizing the corresponding
likelihood with respect to rest of parameters gives Beal and Sheiner estimates. This method
gives desired results in some situations but gives significantly biased estimates, i.e. when
fi (φ, bi ) is significantly non-linear in bi .

3.1.3

Conditional First-order method

The conditional first-order algorithm also uses a first order Taylor expansion, but it expands
at both estimates of the random effects, bi = bˆi and and estimate of other parameters,
denoted by a vector φ. Next we describe the algorithm.
Step 1, set the initial values D0 and σ02 , the estimates of φ̂ and b̂i are obtained by minimizing,
m 

X
1
2
0 −1
||y
−
f
(φ,
b
)||
+
b
D
b
i
i
i
i
i 0
σ02
i=1

(3.9)

Step 2, expand the model fi (φ, bi ) around bi = b̂i and φ = φ̂,
yi ≈ fi (φ̂, b̂i ) + fi0 (φ̂, b̂i )(φ − φ̂) + fi0 (φ̂, b̂i )(bi − b̂i ) + i

29

(3.10)

Chapter 3. Literature review on statistical approaches for population PK/PD models
Then yi approximately follows normal with different expectation fi (φ̂, b̂i ) + fi0 (φ̂, b̂i )(φ −
φ̂) − fi0 (φ̂, b̂i )b̂i and same covariance as in first-order method. This becomes a linear mixed
effect problem and φ̂, σ̂ 2 and D̂ maximize the approximate likelihood.
Step 3, set σ02 = σ̂ 2 and D02 = D̂2 , repeat step 1 and 2 until convergence.
See more details in Davidian and Giltinan’s book and Wolfinger 1993 are good references
on this approach.

3.1.4

Laplacian Method

The Laplacian method evaluates the exact marginal likelihood by using a second-order
Taylor expansion of li around the empirical Bayes estimate bi . Let the first and second
derivatives of li describe as
∂li
∂bi
∂ 2 li
00
li =
∂bi ∂bTi
0

li =

Thus
1
0
00
li = li (b̂i ) + li (b̂)(bi − b̂i ) + (bi − b̂i )T li (bˆi )(bi − b̂i )
2
1
T 00
= li (b̂i ) + (bi − b̂i ) li (b̂i )(bi − b̂i )
2

(3.11)

Consequently, the integral in can be approximated by 3.11. See more details in Wolfinger
(1993) and Davidian and Giltinan (1995).

3.1.5

Lindstrom and Bates algorithm

The Lindstrom and Bates algorithm can be derived using Laplacian approximation. The
estimation algorithm use a combination of a penalized nonlinear least-square estimate
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(PNLS) and a linear mixed-effect estimate (LME). They used a first-order Taylor expansion on the conditional estimates of the individual random effect. To simplify the notations, denote the covariance matrix for random effect D−1 = σ −2 ∆T ∆. In the penalized
nonlinear least-squares, the random effects bi and the estimate of the fixed effect β based
on the current estimate of Φ are obtained by minimizing the function as follows,
OP N LS

N
X
=
(yi − fi (zi , θi ))T (yi − fi (zi , θi )) + bTi ∆T ∆bi

(3.12)

i=1

In order to update the estimate of Φ, the mean function f (·) is linearized using a first-order
Taylor expansion around the current estimate of β and the estimate of bi . The approximate
log-likelihood function for the estimation of Φ can be written as
(
PN
N
X
n
1
∂fi
∂f T
i
2
2
logL(θ, σ , ∆) = − i=1 log(2πσ ) −
log(I + T ∆−1 ∆T iT )
2
2 i=1
∂bi
∂bi
∂fi T i
∂fi T iT  ∂fi −1 T ∂fiT −1 h
I+ T ∆ ∆
yi −fi (bi , θi )+
b̂i
b̂i
+ yi −fi (bi , θi )+
∂bi
∂bi
∂bi
∂bTi
h

)

There are more methods besides our review i.e. adaptive Gaussian quadrature in SAS,
stochastic approximation expectation maximization. Vonesh and Carter (1987) proposed
the use of estimated generalized least squares and establish the asymptotic properties of
the resulting estimates. An alternative method is the use of iteratively weighted generalized least squares. The MIXNLIN program also implements pseudo maximum likelihood
and restricted maximum likelihood estimation by embedding the EM algorithm within a
re-weighted generalized least squares routine. The expansion is either about 0 or about
the empirical best linear unbiased predictor of the inter-individual random effects. All approaches started first from initial estimates set to the true values and second using altered
values. Roe et al. (1997) and Duffull et al. (2005) provide a systematic comparisons of
these population modeling and a summary of the estimation algorithms.
The success of the statistical techniques nowadays are directly related to the availability
of reliable, efficient and user-friendly software for its application. In pharmacology, non-

31

Chapter 3. Literature review on statistical approaches for population PK/PD models

linear mixed effects models are the most common method to describe pharmacokinetics
and pharmacodynamic relationship. It is very useful for mapping out many different kinds
of dose-response curves. In this section we briefly review 3 widely used packages.
The first one, NONMEN software was developed by Beal and Sheiner (1980) and has
been widely used by practitioners to implement PK/PD data analysis. It performs maximum likelihood estimation based on several approximation of log-likelihood function,
such as first-order, first-order conditional estimation methods and Laplacian method. This
software has various attractive features thus it is generally regarded as the gold standard
software for PK/PD modeling and fitting non-linear mixed effects models. NONMEN can
fit the standard PK/PD compartment models. Moreover, it can handle the multiple dosing
regimen in the model. More importantly, it can fit models expressed by the system of
ordinary differential equations. In general, NONMEN is quite accurate, stable, flexible to
fit PK/PD models.
The second one, R/S-plus package nlme can also be used to fit nonlinear mixed effect
model. This package can not only fit two levels of random effect of PK/PD models but
the multiple-level model non-PK/PD models. nlme also has many functions to be used for
modeling checking, plotting as well as diagnostics. nlme itself cannot handle compartment
models expressed by ODE’s without closed-form solution. It requires using an ODE solver
to these PK/PD models. nlmeODE package combines nlme with the odesolve package in
R. The odesolve package provides an interface to the Fortan ODE solver Isoda, which can
be used to solve initial value problems for systems of first-order ODE’s. The computation
times are usually significantly longer using nlme with nlmeODE compared to NONMEN.
The NLMIXED procedure in SAS is also widely used to fit non-linear mixed effects
models. PROC NLMIXED uses integration approximation methods to optimize the objective function. Thus it can be viewed as giving the “exact answer” to the optimization
problem. The advantage of NLMIXED procedure is that it allows users to specify the like-
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lihood function. In SAS, it is very easy to perform exploratory analysis, manipulate data
and perform diagnostics. The output can be directed to files in a variety of formats using
the SAS Output Delivery System. The NLMIXED procedure is quite sensitive to starting
values and parameterizations of the model.

3.2

Bayesian Hierarchical Models

A Bayesian hierarchical model can be considered as the analogous of the mixed effect
models in the frequentist statistical approach. Historically, the implementation of Bayesian
analyses in complex statistical models is not computationally feasible. However, the development of MCMC techniques in the early 1990s have made posterior inference feasible. MCMC techniques can produce samples from the relevant posterior distributions,
from which any desired function of the parameters of interest may then be approximated.
For population PK/PD models, MCMC algorithms may be more difficult to implement
because of the complexity of the mean functions and the nature of the data. Thus, the
implementation in available software such as WinBUGs and PKBugs may be more challenging. Rosner and Muller (1994) and Wakefield et al. (1994) provided the first examples
of a Bayesian approach in the analysis of PK/PD data. In this section, we present a complete Bayesian approach for a population PK/PD model originally developed by Lunn et
al. (2002) and briefly mention the available softwares.

3.2.1

Bayesian Emax based model for population PK/PD model inference

First we present a simple Bayesian model for inference on population PK-PD model. Let
yij denote the PK response for ith subject at observed time point j, i = 1, 2, · · · , m;
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j = 1, · · · , ni . Let θi denote the p-dimensional vector of PK parameters for individual i
2
denote the PK variance for the measurement noise. The sampling distribution is
and σpk

assumed to be normal,
2
),
p(yij |θ i , σ 2 ) ∼ N (f (θ i , tij , Di ), σpk

(3.13)

where the yij s are either concentration or log-concentrations measurement depending
whether normality or log-normality is the most appropriate assumption for the data. f (·)
is a function of individual-specific parameters θ i , observed time tij and the dosing history,
Di . Assign a p-dimensional multivariate normal prior distribution. The individual-specific
PK parameter vector θ i is then,
p(θ i ) ∼ Np (Zi µ, Σ)

(3.14)

where Zi is a p × q covariate-effect design matrix for individual i, µ is a population-level
vector of coefficients and Σ (p × p) represents the population-level variance-covariance
matrix.
2
The model is completed by assuming a prior on the population-level parameters, σpk
,

µ and Σ,
2
∼ IG(a, b);
σpk

µ ∼ Nq (η, H);

Σ ∼ IW (R, ρ)

(3.15)

where IG(·, ·) and IW (·, ·) denote the inverse-gamma and inverse-Wishart distributions,
respectively. The hyper-parameters a, b, η, H, R and ρ are fixed based on available prior
information.
If PK modeling is of interest, then relevant inference focuses on the population level
2
parameters, σpk
, µ and Σ. However, where the drug effect has been measured, the PK

model becomes of intermediate interest, to predict drug concentrations in a certain ”effect
compartment”. These concentration measurements are then used as a primary predictor

34

Chapter 3. Literature review on statistical approaches for population PK/PD models

(input) to construct a realistic model for drug effects that allow the relationship between
efficacy and various covariates to be explored.
As outlined in section 2.2, PD data types are diverse. For example, they can be reported
by binary responses (e.g. presence of disease) or count data (e.g. the number of episode
of a particular condition). Logistic models and poisson regression models respectively
would be required in these cases. Here, for simplicity, we focus only on a continuous PD
response. Let eij 0 denote the drug response for subject i measured at j 0 time point, for
i = 1, · · · , m and j 0 = 1, · · · , n0i . φi is a p0 -dimensional vector of individual-specific PD
parameter. The sampling distribution is described as
2
2
2
eij 0 |φi , θi , σpk
, σpd
∼ N (f 0 (φi ; θi ; tij 0 ), σpd
),

(3.16)

where f 0 (·) is the function of individual-specific PD parameters φi . In general, the PK
model is a compartmental model so one can describe concentrations profile at the ”effect
compartment”. Thus we assume the dynamics depend upon the kinetics only through the
”effect compartment” concentrations, Ce (·):
f 0 (φi ; θi ; tij 0 ) = h(φi , Ce (θi , tij 0 ; Di ))

(3.17)

A simple PK/PD ”link model” can then be identified as,
2
2
p(eij 0 |φi , θi ; σpd
) = N (h(φi ; Ce ); σpd
)

(3.18)

where the function h(·) is given by the classic Emax formula described by
h=

Emax × Ce
φi1 Ce
=
Ce + C50
Ce + φi2

(3.19)

where φi1 and φi2 indicating maximal effect and the concentration where the drug effect
reaches maximal for subject i.
Similar as in the PK model, the hierarchical model for the PD response is expressed
by
p(φi ) ∼ Np0 (Zi0 µ0 , Σpd )

(3.20)
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2
σpd
∼ IG(a0 , b0 );

µ0 ∼ Ns (η 0 , H 0 );

Σpd ∼ IW (R0 , ρ0 )

(3.21)

Here Zi0 is an p0 × s covariance-effect design matrix, µ0 is a vector of s fixed effect parameters, and Σpd is p0 × p0 covariance matrix for PD parameters.
In the following, we denote the matrix of all observed PK data Y = yij , i = 1, · · · m
and j = 1, · · · , ni , and similarly let E denote all observed PD data. And let P be the set
2
2
of population parameter of interest, i.e. µ, µ0 , Σpk , Σpd , σpk
, σpd
.

A typical Bayesian analysis involves estimation of the joint posterior distribution of
all unobserved quantities conditional on the observed data. Bayes’ theorem allows us to
express the posterior distribution as follows,
p(θ, φ, P |Y, E) =

p(Y, E|θ, φ, P )p(θ, φ, P )
p(Y, E)

∝ p(Y, E|θ, φ, P )p(θ, φ, P )
= p(Y, E, θ, φ|P )p(P )

(3.22)

More specifically, p(Y, E, θ, φ|P ) in equation 3.22 can be written as
p(Y, E, θ, φ|P ) =

nQ

m
i=1

Qn0i

o
o nQ Q
m
ni
2
×
i=1
j=1 p(yij |θi , σpk )
o
on Q
nQ
m
m
0
0
p(θ
|µ,
Σ)
(3.23)
p(φ
|θ
,
µ
,
Σ
)
×
i
i i
i=1
i=1

2
j=1 p(eij 0 |φi , θi , σpd )

which is the full likelihood function included in the model. The distribution on
2
2
p(P ) = p(µ)p(µ0 )p(Σpk )p(Σpd )p(σpk
)p(σpd
).

(3.24)

The posterior is proportional to the multiplication of 3.23 and 3.24. This is the whole
structure of a complete PK/PD model.
We can use MCMC methods to explore the joint posterior distribution of interest. We
can infer any interested quantity as long as their realization can be generated in an ergodic
Markov chain sequence of draws from full-conditional distributions. Monte Carlo simulation from a Markov chain requires that the the stationary distribution is the target posterior.
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There are various algorithms for computing, such as Gibbs sampling, Metropolis-Hastings.
The Gibbs sampler is the primary tool to iteratively simulate each quantity from the full
conditional distribution. Given proper initial values for each qunantity of interest, one
iteration of the Gibbs sampler iterates through sampling across the following densities,
2(0)

(0)

2(0)

(0)

2(0)

(0)

2(0)

(0)

2(0)

2(0)

(0)

θ(1) ∼ p(θ|φ(0) , µ(0) , µ0(0) , σpk , Σpk , σpd , Σpd , E, Y )
φ(1) ∼ p(φ|θ(1) , µ(0) , µ0(0) , σpk , Σpk , σpd , Σpd , E, Y )
(1)

Σpk ∼ p(Σ|φ(1) , θ(1) , µ(0) , µ0(0) , σpk , σpd , Σpd , E, Y )
etc.

(3.25)

After T iterations, we have samples θ(T ) , φ(T ) and P (T ) . When T → ∞,
d

p(θ(T ) , φ(T ) , P (T ) ) ∼ p(θ, φ, P |Y, E)

(3.26)

d

where “∼” represents “convergence in distribution”. If a Gibbs sampler is not suitable,
one can use a MH algorithm, rejection sampling as in Gilks et al. (1992), “slice” sampling
as in Neal et al. (1997).

3.2.2

WinBUGS, PKBUGS and ADAPT

There are three popular programs to implement the PK/PD models. The most popular
and versatile Bayesian program is WinBUGS. The package can handle complex Bayesian
analyses using MCMC methods. Since WinBUG requires a method specification that is
suitable for any class of model, it is not optimal for population PK/PD models. Because
the specification of population PK/PD models for majority of ”real-life” application is
complex, such as the complexity of patients’s dosing histories, time-varying covariates,
censored observations or missing data.
PKBUGS alleviates those difficulties of model specification and thus makes state-ofart MCMC techniques accessible to the analysis of PK-PD models. It is an interface for
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the Bayesian statistical software for the analysis of only pharmacokinetic data. The main
feature of PKBUGS is to simplify the specification of PK modeling by using dialog boxes
and menu commands. It also can recognize the NONMEN data format and a number of
standard data items (like the patients’s id, time and response). The users can regress the
covariates against the desired PK parameters. The structure specifies 28 PK compartment
models with the input characteristics, such as bolus/infusion intravenous, first-order with
initial lag time. PKBUGS is a customized-oriented hierarchical PK model. See more in
Lunn (1999), (2002), Lunn and Aarons (1997), (1998).
ADAPT is another computational modeling platform developed for pharmacokinetics
and pharmacodynamics applications. It provides almost all relevant parametric nonlinear
mixed-effects modeling algorithms, such as the first-order conditional estimation method,
Laplace method, the Monte Carlo parametric Expectation Maximization and MCMC algorithms. It is designed to describe the biological process, such as PK/PD, estimate model
parameters and make inference from model prediction. Bauer et al. (2007) used three published data to compare the results from ADAPT with that of NONMEN and WINBUGS.
He claimed that ADAPTs performance was very stable, more efficiently with more complex PK/PD models involving a system of differential equations. See more applications in
Hong, 2007, Ng CM, 2013, 2010.
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The parametric statistics assume that the data come from a type of probability distributions
and make inference on the parameters of the distribution. These probability distributions
are characterized by a finite number of parameters, i.e. a normal distribution with unknown mean and variance. In contrast, nonparametric statistics avoids assumptions on the
probability distribution, for example a classical nonparametric test, the sign test.
In general, parametric methods make more assumptions than non-parametric methods.
If those assumptions are not violated, parametric methods can produce accurate and precise estimates. However, if the parametric assumptions are violated, parametric methods
can be misleading. For this reason, parametric approaches are not robust. Nonparametric
approaches are robust because they generally do not have assumptions on distributions.
What’s more, when modeling a distribution over data, parametric models use a fixed and
finite number of parameters. Thus, they can suffer from over- and under-fitting of the data.
It becomes difficult to balance between the complexity of the model and the amount of
data available. In this situation, non-parametric Bayes provides an alternative approach to
parametric modeling and allows the number of parameters to change when more data are
collected. Thus it can avoid under-fitting and over-fitting of the model.
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Suppose we have an underlying and unknown distribution which we wish to infer given
some observed data. Say, we observe x1 , x2 , · · · , with xi ∼ F . In other words, we assume
that the observations are independent and identical draws from F . A Bayesian would
approach this problem by placing a prior over F , then computing the posterior over F
given data. Traditionally these models and priors are chosen from a parametric family.
However, restricting distributions to a certain parametric family may limit the scope and
type of inference that can be made. The nonparametric Bayesian approach uses a prior
with a wide support, i.e. prior distribution can change with more data observed. We can
make different types of inference given a large space when posterior computations are
tractable.
The Dirichlet process (DP) is one of the most popular Bayesian nonparametric models.
Ferguson et al. (1973) first formalized it for general Bayesian statistical modeling. DP can
be succinctly described as a distribution over distributions, i.e. each draw from a DP is a
distribution itself. It is called a DP because it is characterised by Dirichlet distributed finite
dimensional marginal distributions. This is similar to a Gaussian process, where the finite
dimensional marginal distribution are Gaussian distributions. But the distributions drawn
from a DP are discrete, and they can not described using a finite number of parameters.
Since the random draw from DP is a discrete distribution, it is often used for clustering
the population into heterogeneous subpopulation. In this chapter, we introduce the DP and
DP mixture model with MCMC techniques in the Bayesian framework. In section 4.1, we
present the Dirichlet Process and its properties. Section 4.2 discusses DP mixture model.
In section 4.3, we discuss a modern MCMC sampling algorithm of Bayesian inference in
DP mixture model.
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4.1

The Dirichlet Process

The Dirichlet Process (Ferguson, 1973) is one of the most widely used Bayesian nonparametric models for modeling unknown random distributions in Bayesian statistics. It has
been applied to a wide range of problems, such as variable selection in genetics (Kim et
al. 2006), linguistics (Teh, 2006b), psychology (Navarro et al., 2006, image segmentation
(Sudderth and Jordan, 2009) as well as in the neurosciences (Jbabdi et al., 2009). In this
section, we will review the popular representations of DP in Bayesian framework.

4.1.1

Definitions

There are many ways to define a Dirichlet process. Before we proceed to a formal definition, let us see an intuitive definition first. Consider a Bayesian mixture model consisting
of K components,
xi |zi , θk? ∼ F (θk? )

(4.1)

with
zi |πα ∼ Multinomial(πα );

πα ∼ Dir(α/K, · · · , α/K);

θk? |H ∼ H

(4.2)

where πα denotes the vector of mixing proportion, α is the concentration parameter in Dirichlet distribution, and H is a distribution over θk? . F is a parametric distribution indexed
P
?
by θi . Then xi ∼ K
k=1 πk F (θk ) which defines a finite mixture model. Here xi s are random draws from a component whose distribution parameterized by θk? . Each observation
xi has a class label zi indicating which component xi is from. zi follows a multinomial
distribution with a parameter vector from a Dirichlet distribution. When K → ∞, we
obtain an infinite mixture model.
Ferguson (1973) first developed DP considering its finite dimensional distributions.
For a random distribution G ∼ DP (α, H), its marginal distributions must be Dirichlet
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distributed. A formal definition is that we say G is a Dirichlet process with base distribution H and concentration parameter α, written G ∼ DP (α, H), if
(G(A1 ), G(A2 ), · · · , G(Ar )) ∼ Dir(αH(A1 ), αH(A2 ), · · · , αH(Ar ))

(4.3)

for any finite measurable partition A1 , · · · , Ar of Ω. Here Dir(γ1 , · · · , γk ) denotes the
k-dimensional Dirichlet distribution with parameters γ1 , · · · , γk .
The parameters H and α play an intuitive role in the definition of DP. The base distribution is the mean of the DP. For a measurable set A ∈ Ω, we have E[G(A)] = H(A). On
the other hand, the concentration parameter can be understood as a precision parameter:
V ar[G(A)] =

αH(A)(α−αH(A))
α2 (α+1)

=

H(A)(1−H(A))
.
α+1

The larger α is, the smaller the variance,

and then DP will concentrate more of its mass around the mean. α is also called strength
parameter referring to the strength of the prior when using DP as a prior in a Bayesian
nonparametric model. See more explanation in posterior distribution of DP next.

4.1.2

Properties of Dirichlet Process

The DP has several well-known representations and properties. Here we give a brief summary.

Polya Urn Scheme and De Finetti’s Theorem
Polya Urn scheme provides a visualization of DP (Blackwell and Macqueen, 1973). More
importantly, it can be used to prove the existence of DP. Here we introduce the Polya Urn
scheme first and discuss the existence of DP. Suppose each value in the space Ω has a
unique color. In the beginning, there are no balls in the urn. First pick a color from H, i.e.
θ ∼ H, paint a ball with that color and drop it into urn. Second, either pick a ball from the
urn, paint a new ball with the same color, then drop both balls into the urn; or draw a new
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color from H, paint a ball with that color, and drop it into the urn. In the subsequent steps,
for the (n + 1)th time, draw a color from H with probability

α
α+n

, paint a new ball with

that color and drop the ball into the urn; or choose a ball from the urn with probability
n
,
α+n

paint a new ball with the same color and drop two balls back into urn. The color of

an infinite sequence of draws follows a DP with strength parameter α and base distribution
H.
The distribution over the color of ball represents the DP. The distribution of new ball
color depends the distribution of existing color and the base measure H. The sequence
of ball colors has an exchangeability property. Consider a finite sequence of ball colors,
θ1 , . . . , θn , then we can define a distribution over the first n ball’s color as,
P (θ1 , . . . , θn ) =

n
Y

P (θi |θ1 , . . . , θn−1 )

(4.4)

i=1

The right-hand side in 4.4 is the same as any sequences of n elements from H. For example, given any permutation σ of {1, 2, . . . , n}, it is not difficult to show,
P (θ1 , . . . , θn ) = P (θσ(1) , . . . , θσ(n−1) ).

(4.5)

The joint density of a sequence of draws are equal to the joint density of any permutation of the sequence. This can be extended to the infinite sequence of DP. De Finetti’s
theorem states that for any infinitely exchangeable sequence, θ1 , θ2 , . . . , there is a random
distribution such that the sequence of independently identical draws are from it,
Z Y
n
P (θ1 , . . . , θn ) =
G(θi )dP (G)

(4.6)

i=1

In this setting, G ∼ DP (α, H) is the mixing De Finetti’s measure.

Posterior distribution
Here we explore the posterior distribution of a DP. Let G ∼ DP (α, H). Since G is a
random distribution, we can draw samples from G. Let θ1 , θ2 , · · · , θn be a random sample
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from G. We are interested in the posterior distribution of G given θi . To examine it, let
A1 , . . . , Ar be a finite partition of parameter space Ω. Let nk denote the number of θs in
Ak , nk = #{i : θi ∈ Ak }. G ∼ DP (α, H), by definition of DP,
(G(A1 ), G(A2 ), · · · , G(Ar ) | θ1 , θ2 , · · · , θn )
∼ Dir(αH(A1 ) + n1 , αH(A2 ) + n2 , · · · , αH(Ar ) + nr )
Since it is true for any partition of Ω, the posterior of distribution of G must be a DP too.
Now we can figure out the updated parameters for the posterior. The new concentration
parameter is equal to αH(A1 ) + n1 + · · · + αH(Ar ) + nr = α + n. The new base
distribution is a mixture of the empirical cumulative distribution function of θ’s and n,
written as

P
αH+ n
i=1 δθi
,
α+n

where δ· is the point mass at θi . The posterior can be rewritten as

n
α
H+
G|θ1 , θ2 , · · · , θn ∼ DP (α + n,
α+n
α+n

Pn

i=1 δθi

n

)

(4.7)

The posterior base distribution is a weighted average between the prior base distribution
P
H and the empirical distribution ni=1 δθi . The weight associated to n has weight proportional to α and the empirical distribution has weight proportional to the number of
observations n. From this representation, it follows that α can be interpreted as a strength
parameter referring the strength of the prior.

Predictive Distribution
Now we explore the predictive distribution of draws from a DP. Since G|θ1 , · · · , θn is a
DP, we have

p(θn+1 ∈ A|θ1 , · · · , θn ) = E(G(A)|θ1 , · · · , θn )
n

α
1 X
δθ ,
=
H(A) +
α+n
α + n i=1 i
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for any measurable set A ∈ Ω, where the last step is the posterior base distribution of G
given the first n observations. Marginalizing out G, we obtain the predictive distribution,
n

α
1 X
θn+1 |θ1 , · · · , θn ∼
H+
δθ
α+n
α + n i=1 i

(4.8)

Given the posterior base measure is also the predictive distribution of θn+1 . When α →
0, the prior becomes non-informative, that is the predictive distribution is given by the
empirical distribution. When the number of observations is large, n >> α, the predictive
distribution is dominated by the base distribution which is also close to the underlying
distribution. This indicates the property of the DP: the posterior of DP converges to the
true underlying distribution. We can also see that DP is discrete with sum of probability
one. Equation 4.8 helps us to understand that each draw from DP is a distribution. The
first draw θ1 can be defined as a point mass at θi . The distribution of the second draw is
θ2 |θ1 ∼

α
H
α+1

1
θ
α+1 1

+

and so on. The DP can be succinctly described as a distribution

over distributions.
The predictive distribution can often be characterized as a species sampling(SS) allocation rule. More formally, a SS sequence is a sequence of random variables θ1 , θ2 , · · · ,
characterized by the predictive probability function,
P {θn+1 ∈ ·|θ1 , · · · , θn } =

n
X

qn,j δθj (·) + qn,n+1 H

(4.9)

j=1

Here qn,j =

1
α+n

and qn,n+1 =

α
α+n

are non-negative values with

Pn+1
j=1

qn,j = 1. H is a

non-atomic probability measure (Pitman, 1996b). Considering the unique values of θj , the
equation 4.9 can be rewritten as
P {θn+1 ∈ ·|θ1 , · · · , θn } =

Kn
X

?
qj? δθj? (·) + qK
H,
n +1

(4.10)

j=1
?
where Kn is the number of unique values, say (θ1? , · · · , θK
) are the unique elements in the
n

sample of (θ1 , · · · , θn ). qj? s are the normalizing constants. Here qj? only depends on the
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frequency of θj occurring. From 4.10, we know that the value θk? will be drawn θn+1 with
probability proportion to nk , the number of times the value has already been observed. In
the first n draws, the larger nk is, the higher the probability that the new draw θn+1 equals
to θk? . This is a rich-gets-richer phenomenon, where large clusters (a set of θi with same θk? )
grows larger fast. It also shows the clustering property of the DP by looking at partitions
induced by the clustering. The unique values of θ1 , . . . , θn induce a partitioning of the set
[n] = {1, . . . , n} into clusters such that in each cluster, θi ’s take on the same values θk? .
Since θ1 , . . . , θn are random, this induces a random partition of [n]. Larger nk and lower
value of α imply a tighter clustering.
The Chinese Restaurant Process (CRP) is another popular metaphor used to interpret
DP. Imagine a Chinese restaurant with an infinite number of tables, and a sequence of
customers are waiting for entering. The first customer enters and sits at the first table. The
second customer enters and sits either with the first customer at first table with probability

1
,
1+α

or sits at a new table with probability

α
.
1+α

In the subsequent steps, nth

customer comes, he/she can sit at occupied table K with the probability

k
,
n−1+α

where

k represents the number of previous customers already sitting at table K, or at a new
table with probability

α
.
n−1+α

Identifying customers with integers 1, 2, . . . and tables as

clusters, n customers define a partition of [n]. CRP defines a distribution over partitions
of [k],k = 1, 2, · · · , K. The value of k is the number of customers. The distribution over
tables is a DP.

Stick-breaking Construction

Another representation of the Dirichlet process is provided by the stick-breaking construction (Sethuraman, 1994, Pitman, 1996). This process can be used to provide a constructive
algorithm for generating a DP. The distribution of DP is given by the density of a weighted
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sum of point masses.
G=

K
X

πk δθk?

k=1

(4.11)

with πk = βk

k−1
Y

(1 − βi );

βk ∼ Beta(1, α);

θk? ∼ H

i=1

The construction of π can be understood as starting with a stick of length 1. Break it at
β1 , assigning π1 to be the length of stick we just broke off, assign πi on a draw θi from H.
Break the remaining portion of the stick at β2 with the breaking off length π2 , assign π2 as
a corresponding weight for the second draw θ2 from H. Recursively break the remaining
portion to obtain π3 and so forth. The stick-breaking distribution over π is written as
π ∼ GEM (α), where the letters stand for Griffiths, Engen and McCloskey.
This representation is the most versatile definition of the Dirichlet process. It has been
explored to generate efficient alternative MCMC algorithms. It is also the basis of the
definition of the generalizations that allow dependence across a collection of distributions,
i.e. dependent Dirichlet process (MacEachern, 2000, Griffin and Steel (2006)).

4.2

Dirichlet Process Mixture model

Dirichlet process mixture models go back to Antoniak (1974) and Ferguson (1973). They
have been developed by Escobar and West (1995), MacEachern and Muller (1998). DPM
is one of the most classic models in nonparametric Bayesian. It defines a mixture model
with countably infinitely components and can be used in density estimation or clustering
while the number of components is a priori unknown. DPM have become increasingly
popular for modeling when traditional parametric models impose unreasonably constraints
on the distribution. Examples of applications includes empirical Bayes problems (Escobar,
1994), nonparametric regression (Muller, Erkanli, and West (1996)), density estimation
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(Escobar and West 1995), hierarchical modeling (MacEachern 1994, West, Muller, and
Escobar 1994).
The core of the DPM model can basically be thought of as a simple Bayesian model.
Data y1 , · · · , yn are independently draws from unknown distribution F . The prior is θi ∼
G. Here we add uncertainty about the prior distribution G, instead of using a distribution
from the exponential family.
yi |θi ∼ F (θi ),

θi |G ∼ G,

G ∼ DP (α, H)

(4.12)

where G is a random distribution from DP with base measure H and concentration parameter α, F (·) is an unknown distribution with parameter θi . The general applications of
DPM typically allow the introduction of subject-specific covariates. And the more complex models also introduce distributions on the hyper-parameters on F , α and H.
Before we move to estimate the DPM and discuss MCMC sampling algorithms, we
need to briefly prove that an equivalent limiting process of a Dirichlet process mixture
model. This limiting process can improve the sampling efficiency. We start with a finite
mixture model with k components. The likelihood function can be written as
p(y1 , · · · , yn ) =

k
Y
j=1

πj

n
Y

p(yi |θj )

(4.13)

i∈j

where πj is the mixing proportion for component j with

P

πj = 1. p(·|θj ) is the probab-

ility density function for component j with parameter θj . Here we first consider the model
for a fixed k components, then explore more properties as k → ∞.
The mixing proportions πj , are given a symmetric Dirichlet prior with parameter
α/k, · · · , α/k:
k
Γ(α) Y α/k−1
p(π1 , · · · , πk |α) ∼ D(α/k, · · · , α/k) =
π
Γ(α/k)k j=1 j
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Here we introduce an indicator variable ci to “label” which component generates xi . ci s
takes on values 1, · · · , k. The joint distribution of the ci s is multinomial with parameter
π = π1 , · · · , πk expressed,
p(c1 , · · · , cn |π) ∝

k
Y

n

πj j ,

nj =

j=1

n
X

δci (j)

(4.15)

i=1

Integrating out the mixing proportions π, the joint density of c1 , · · · , cn ,
Z
p(c1 , · · · , ck ) =

p(c1 , · · · , ck |π1 , · · · , πk )dπ1 , · · · , dπk

Γ(α)
=
Γ(α/k)k
=

Z Y
k

n +α/k−1

πj j

dπj

j=1
k
Y

Γ(α)
Γ(nj + α/k)
Γ(n + α) j=1 Γ(α/k)

(4.16)

In order to use Gibbs sampling to update ci in MCMC simulation, we need investigate the
conditional prior ci given the rest of labels, denoted as ci |c−i . Assuming ci = c,
p(ci = c|c−i ) = p(c1 , · · · , ci = c, · · · , cn )/p(c1 , · · · , ci−1 , ci+1 , · · · , cn )
R
(α/k)−1
(α/k)−1
Γ(α)
pc1 , · · · , pci =c , · · · , pcn Γ(α/k)
, · · · , pk
dp
−k p1
=R
(α/k)−1
(α/k)−1
Γ(α)
, · · · , pk
dp
pc1 , · · · , pci−1 , pci+1 , · · · , pcn Γ(α/k)
−k p1
=

n−i,j
α/k
+
n−1+α n−1+α

(4.17)

In summary, the above finite mixture model can be expressed hierarchically as follows,
yi |ci , φci ∼ f (yi |φci )

(4.18)

with
c|π1:k ∼ Dis(π1 , . . . , πk );

φci ∼ H(θi );

π1 , . . . , πk ∼ Dir(α/k, . . . , α/k)
(4.19)
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where Dis denotes the discrete distribution. Dir represents the Dirichlet process. When
k → ∞, the conditional probabilities defining the prior for the ci reach the limits,

(4.20) p(ci = c|c−i ) →

n−i,c
n−1+α

If ci 6= cj for all j 6= i,

(4.21) p(ci |c−i ) →

n−i,c
n−1+α

This limiting process is equivalent to Dirichlet process mixture model if we consider θi =
φci .

4.3

Inference samplings in DPM model

Use of DPM models has become computationally feasible with the development of
Markov chain methods for sampling from the posterior distribution. Methods based on
Gibbs sampling can be easily to implement in the model based on conjugate prior. However, in non-conjugate case, it is difficult to carry out because of the difficulty of solving
numerical integral. West, Muller and Escobar (1994) used a Monte Carlo approximation to
the integral. MacEchern and Muller (1998) developed an exact method for non-conjugate
priors. They used a mapping from a set of auxiliary parameters to the set of parameters
currently in use. Neal (2000) presented a comprehensive survey of MCMC sampling in DP
mixture models for both conjugate and non-conjugate priors. In our real application, the
prior is not conjugate but we developed a modern sampling algorithm that is suitable for
our special population PK/PD data. Here we first introduce a simple sampling algorithm
for a conjugate prior, and then move to a complex algorithm for non-conjugate case.

50

Chapter 4. Bayesian Nonparametric Modeling

Since a draw from a DP is discrete random distribution. Given a sequence of random
draws θ1 , · · · , θn , the prior distribution of the θi can be expressed as
θi |θ−i ∼

X
1
α
H
δθ j +
n − 1 + α j6=i
n−1+α

(4.22)

where δθ is the point mass at θj .
Given the likelihood and prior, the posterior distribution θi |θ−i , the posterior distribution θi |θ−i , yi is,
X
α
1
p(yi |θj )δθj +
p(yi |θi )H(θ)
i − 1 + α j6=i
i−1+α
Z
X
1
α
=
p(yi |θj )δθj +
p(θ|yi , H) p(yi |θi )dH(θ)
i − 1 + α j6=i
i−1+α

θi |θ−i , yi ∼
(4.23)

where p(θi |yi , H) is the posterior distribution of θ based on an observation yi and H. If
H is conjugate prior for the likelihood F , we can use Gibbs sampling to repeatedly draw
the new values from 4.23 and then make inference about θi . Because it is not difficult
R
to compute the integral p(yi |θi )dH(θ) and sampling from p(θi |yi , H). Escobar (1994)
and Escobar and West (1995) presented a simple algorithm based on equation 4.23. The
sampling is not efficient because of two reasons. First, when we update θi , it goes through
the low-probability states before reaching to the highest probability state. It becomes
slower if we have more states in practice. Second, we can only renew θi no more once at
each iteration.
Bush and MacEachern (1996) and West, Muller and Escobar (1994) improved this
algorithm by borrowing the strength of the limiting process. The basic idea is to assign
a cluster label ci for yi , update ci using the required probability for i = 1, · · · , n. Some
observations are assigned into several groups. In each group, we may have one or more
observations and then we can sample θci =c given yi ∈ c. This algorithm allows us to
change θi at least twice and it may pass through the inter-mediate state fast. Here we
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presents more details about the implementation. The permanent chain includes {ci , θi }.
We take updating θi as an example. To keep the simplicity of the notation, let c−i denote
the all cj s , j 6= i, similarly for θ−i too. k − denotes the number of distinct values of θ−i or
c−i . If ci = cj for some j 6= is, the required conditional probability is,
p(ci = c|c−i , θi , yi ) ∝

n−i,c
p(yi |θc )
n−1+α

(4.24)

where n−i,c denotes the number of c−i = c. If ci 6= cj for all cj s, j 6= i, the conditional
probability for ci is
α
p(ci =
6 cj |ci , θ−i ) ∝
n−1+α

Z
p(yi , θ)dH(θ)

(4.25)

Using the equation 4.24 and 4.25, we can update ci for i = 1, · · · , n. Suppose that we
have K groups in total after updating the cluster label. In each group, we may have several
observations. Therefore, we can sample θk using Metropolis-Hastings algorithm.
If H is a non-conjugate prior on F , it is difficult to compute the integral, especially
in high-dimensional cases. In order to avoid the integral computation and create a chain
mixing fast, we implement an adaptive MCMC algorithm, Gibbs sampling with auxiliary
parameters, in our real application.
The basic idea of the modern MCMC algorithm is that we are interested in sampling θi
from p(θi |θ−i , yi ). However, we can not sample it directly because of the integral compuR
tation p(yi , θ)dH(θ). Instead we introduce several auxiliary parameters from H, draw
θi from the conditional distribution p(θi |θ−i , θauxiliary , yi ) and discard θauxiliary during the
Markov chain simulation. We know that the p(θi |θ−i , θauxiliary , yi ) is the marginal distribution p(θi , θauxiliary ). It is easy to see that this update for θi will leave θi |θ−i invariant. In the
end, keep θi and discard θauxiliary s. The sampling process can be expressed as, first, draw
a new value of θauxiliary from H, given p(θi |θ−i ) from the conditional distribution; second,
update θi given the new value of θauxiliary from the first step; third, discard θauxiliary and
keep θi only. Note that the values of θauxiliary are introduced temporarily and they are not
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associated with any observations. This algorithm is called Gibbs sampling with auxiliary
components (Neal et al. (2000)).
Next we show the general steps to implement the algorithm. The permanent state of the
Markov chain has ci and θi . We take sample ci and θi as an example. First we introduce a
number of temporary auxiliary components, denoted θk− +1 , · · · , θk− +m . Here k − denotes
the number of distinct value among cj or θj , j 6= i.
The first step is to update ci based on the conditional distribution ci given all other parameters associated with the observations and the auxiliary parameters. If ci = cj = c for
some js, which means ci ∈ {1, 2, · · · , k − }, independently draw m auxiliary components
from H, the conditional distribution of ci is,
ci |c−i , θ1:k− , θk− +1 , · · · , θk− +m , yi ∝

n−i,c
p(yi , θc )
n−1+α

If ci 6= cj for all j 6= i, assign the class label ci = k − + 1, and let θk

(4.26)
− +1

= θi . We draw the

rest of m − 1 auxiliary components from H. The corresponding distribution is,
p(ci = k − + 1|c−i , θ1:k− , θk− +1 , · · · , θk− +m , yi ) ∝

α/m
p(yi , θc )
n−1+α

(4.27)

where c ∈ (k − + 1, · · · , k − + m). The equation 4.27 shows that θi has an equal probability
to be one of auxiliary parameters.
After updating ci for i = 1, · · · , n, some observations share the same class label which
indicates that they have the same parameter values in a group. We use θ1? , · · · , θk? denote
the distinct values of (θ1 , · · · , θn ). Sampling θc? given all the observations yi , i ∈ c is
straightforward. The target distribution equals the multiplication of the likelihood function
and prior,
p(θk? |yi∈k , ci = k) =

Y

p(yi |θk? )π(θ)

(4.28)

i∈k

To simulate from the target distribution p(θk |·), we start with a starting values θ(0) . At
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iteration T , we draw a proposal θ? from a known proposal distribution q(θ). We accept


θ ? ,
with probability α
(T )
θ =

θT −1 , with probability (1 − α)
with α defined:
n p(θ? |y) q(θ(T −1) |θ? )
α = min
,
p(θ(T −1) |y) q(θ? |θ(T −1) )

o
1

(4.29)

To implement the M-H algorithm, it is important to choose a proposal distribution such
that the chain “mixes well”, i.e. adequately explores the posterior distribution. The popular
choice is the multivariate normal distribution, Bennett Racine-Poon (1996), Carlin and
Louis (1996), and Huang (2004). However, an important issue regarding the multivariate
normal proposal distribution is the dispersion of the proposal density. If the variance of the
proposed density is too large, the large proportion of proposed candidates will be rejected,
and the Markov chain will waste many repeats and result in inefficiency of the algorithm.
On the other hand, if the variance of the proposed density is too small, the chain will
have a high acceptance rate but will move only in a small parameter space, leading to
inefficiency too. Tuning of associated parameters such as proposal variances is crucial to
achieve efficient mixing, but can also be very difficult.
In our MCMC implementation, we consider an automated tuning of MCMC algorithm
Harrio et al. (2001). Adaptive MCMC algorithms can automatically “learn” better parameter values of Markov chain Monte Carlo algorithms while they run because the proposal
variance is the variance of the empirical estimates. We begin with a d-dimensional target
distribution π(·). We perform a Metropolis algorithm with a proposal distribution given at
iteration n by Qn (x, ) = N (θ, (0.1)2 Id /d) for n ≤ 2d, while for n > 2d,
Qn (θ, ·) = (1 − β)N (θ, 2.382 Σn /d) + βN (θ, 0.12 Id /d),

(4.30)

where Σn is the current empirical estimate of the covariance structure of the target distribution based on the run so far, and where β is a small positive constant i.e. β = 0.05, d is
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the dimension of θ, and Σ0 is a fixed non-singular matrix, i.e.

0.12 Id
.
d

It is also necessary to

use some alternative fixed proposal distribution for the first few iterations when the empirical covariance Σn is not yet well-defined. Roberts and Rosenthal (2001) proved that the
proposal N (θ, 2.382 Σn /d) is optimal in a particular high-dimensional context. They also
demonstrate that this adaptive Metropolis algorithm will indeed “learn” the target covariance matrix and approach an optimal algorithm, even in very high dimension. It may takes
many iterations before the adaption significantly improve the algorithm, in the end it will
converge enormously faster than a non-adapted random walk Metropolis algorithm. We
refer the desired readers to see more details and proof in Harrio et al. (2001) and Roberts
and Rosenthal’s multiple publications about adaptive Metropolis, Yang (2007), Saksman
and Vihola (2008), Bai et al. (2008), Atchade and Fort (2008), Craiu et al. 2008 Bai et al.
(2009).
We end this chapter by introducing a sampling step we implemented in our application.
After updating ci for i = 1, · · · , n, assuming that we have K distinct estimates θ1 , · · · , θK ,
we consider that it is a random sample from a population distribution N (µ, Σ). To keep
the notions clearly, we present the whole structure as follows,
θ1 , · · · , θK |µ, Σ ∼ N (µ, Σ)
µ ∼ N (µ0 , Σ0 )
Σ ∼ IW (v0 , Σ−1
iw )

(4.31)

where IW represent the inverse-Wishart distribution with mean

Σ−1
iw
.
v0 −d−1

The values for

µ0 , Σ0 , v0 and Σ−1
iw are known.
The posterior distribution of µ|θ1 , · · · , θk , Σ is expressed as follows by multiplying the
joint likelihood function θ1 , · · · , θK |µ, Σ, and prior,
1

T Σ−1 µ+µT Σ−1 µ }
0
0
0

1

T A µ+µT b }
n
n

p(µ|θ1 , · · · , θK , Σ) ∝ e{− 2 µ
(4.32)

= e{− 2 µ
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Equation 4.32 implies that the conditional distribution of µ must be a multivariate normal
−1
−1 −1
distribution with covariance A−1
= (Σ−1
and mean A−1
0 + KΣ )
n
n bn = (Σ0 +
−1
KΣ−1 )−1 (Σ−1
0 µ0 + KΣ θ̄).

Similarly, given the prior for Σ, the full conditional distribution of Σ given θ 1 , · · · , θ K
and µ can be written as, The conditional distribution of Σ,
−1 )/2

−1 )/2

p(Σ|θ1 , · · · , θK , µ) ∝ |Σ|−(v+p+1)/2 e−tr(v0 S0 Σ
(4.33)

× |Σ|−k/2 e−tr(Sθ Σ
−1 /2

= |Σ|−(v+k+p+1)/2 e−tr(S0 +Sθ )Σ

Thus we have (Σ|·) ∼ W −1 (v0 + k, [S0 + Sθ ]−1 ) with Sθ =

Pk

i=1 (θ i

− µ)(θ i − µ)T . The

result is intuitive. We can think of v0 + k as the “posterior sample size”, the sum of the
prior sample size v0 and the sample size of the data. Similarly, v0 S0 + Sθ can be thought
of as the “prior” residual sum of squares plus the residual sum of squares from the data.
We can use these full conditional distributions to construct a Gibbs sampler which
provides a MCMC approximation to the joint posterior distribution p(µ, Σ|θ1 , . . . , θk ).
Given a starting value Σ(0) , the Gibbs sampler generates {θ s+1 , Σs+1 } from {θ s , Σs },
first from the equation 4.32 for µs+1 and then for Σs+1 from the equation 4.33.
Repeatedly sampling to obtain {(µ(0) , Σ(0) ), · · · , (µ(T ) , Σ(T ) )}. We are interested in
P
P
the posterior means denoted as θ̄post = T1 Tt=1 θ(t) and Σ̄post = T1 Tt=1 Σ(t) . In our
application, we do update µ and Σ given θ1 , · · · , θK at each iteration for both PK and PD.
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Nonparametric Bayes model for a
population PK/PD model

In this chapter, we will present our proposed approach for a population semi-mechanistic
PK-PD model. In section 5.1, we specify our nonparametric Bayes model. Section 5.2
discusses Euler’s approximation. In section 5.3, we will discuss the prediction inference.
In section 5.4, we will present a simulation data and a real data example.

5.1

Nonparameteric Bayesian Hierarchical Model

We consider a simple version of the model here. For the PK model, we use a twocompartmental model to describe PK response measurement, i.e. unbound plasma concentration. We assume that the measurement variation represents inter-subject variability
and an error term. Let yijP K denote the observed j th measurement of the response in the
PK model for subject i at tij for i = 1, · · · , n, j = 1, · · · , ni . The value of n is the number
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of subjects. The PK model can be described as,
yijP K |θiP K = fiP K (θiP K , tij ) + ij

(5.1)

where fi (θiP K , tij ) is a function for predicting the jth response in subject i, θiP K is a vector
of PK parameters. The function f is related to a system of ordinary differential equations,
which “represents” what happens to the drug in the body, see Figure 2.1(c). Mathematically, we use a differential equation to describes the rate of dose change in each compartment, written as,
dxc (t)
CL CLd
CLd
= −( c + c )xc (t) + p xp (t) + r(t)
dt
V
V
V
CL
CLd
dxp (t)
= c xc (t) − p xp (t)
dt
V
V
xc (t)
C(t) =
Vc
where xc and xp denote the amount of drug in the central and peripheral compartment
separately, r(t) is the infusion rate which is different across patients. CL is the system
clearance, V c and V p are volumes of the central and peripheral compartment respectively,
CLd is the inter-compartment clearance. The PK parameter is (CLi , Vic , Vip , CLdi ) for
subject i. C(t) is the time course of unbound plasma concentration.
For PD part, the observed response is the absolute neutrophil count (ANC) for the cancer patients. Neutrophils are key components in the system of defense against infection.
An absence or scarcity of neutrophils (a condition called neutropenia) makes a person vulnerable to infection. After chemotherapy, radiation, the ANC is usually depressed and then
slowly rises, reflecting the fact that the bone marrow is recovering and new blood cells are
beginning to grow and mature. We use a physiology-based PD model to characterize ANC.
The new cells generated in the bone marrow take time to be present in the circulation system. We use a five compartmental model to represent the whole process. We prefer this
structure model because of three followed reasons. First, it can separate the system-related
parameters which are common across patients, and a drug-related parameter. Second, it
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includes three transits compartments which allow us to predict the time delay between the
drug effect site and observing site. The third reason is that we can use the full time course
of drug concentrations as a special covariate in the PD model. The whole structure consists
five compartments, a stem or progenitor compartment, denoted as P rol, three maturation
compartments, denoted as T rasit, and the circulation compartment Circ, which represent
the observed circulating cells, see Figure 6.1.
The first differential equation in 5.2 describes the rate of the number of stem/progenitor
cells change in the proliferation compartment. The rate of cell change is affected by the difference between the proliferation rate and elimination rate. If the generation rate is greater
than the elimination rate, the proliferation rate will increase, otherwise reverse. Moreover,
the proliferation and elimination rate can be influenced by the number cells in the proliferation compartment. More cells in bone marrow, the higher generation rate is. However,
these stem and progenitor cells are sensitive to the drug. The drug is assumed to induce the
cell division and generation and the magnitude of drug effect is highly dependent by the
drug concentration, E = slope × Conc or Emax model, Emax × Conc/(EC50 ∗ Conc).
Additionally, a rebound cells from the circulation compartment can affect the proliferation
rate called a feedback effect (Circ0 /Circ)γ . The first differential equation is nonlinear
with the rebound parameter, γ. The committed cell in the bone marrow goes through three
transit compartments, and then can be observed in Circ compartment. If more cells go
into a compartment and less go out, the rate of amount of cell will increase and otherwise
decrease. The mechanism is the same for the last four compartments. Moreover, we also
assume that the only cell loss is the cell “go” to next compartment, thus the proliferation
rate, transit rate and the circulation rate should be equal at the steady state, i.e. t = 0.
A system of nonlinear differential equations are used to describe the whole mechanism process. The corresponding parameters include the baseline value of ANC (Circ0 ),
mean transit time (MTT), a drug related parameter (slope) and a feedback parameter (γ).
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MTT represents the average time for a new generated cell to pass through the transit compartments before entering the circulation compartment. MTT has an inverse association
with the transit rate, ktr , defined as M T T = (n + 1)/ktr where n is the number of transit
compartments. Slope parameter is a fixed constant connecting drug concentration in the
central compartment and drug effect. The parameter γ describes the strength of rebound
cells from the circulation compartment.
dP rol
dt
dT ransit1
dt
dT ransit2
dt
dT ransit3
dt
dCirc
dt

= kprol P rol(1 − Edrug )(

Circ0 γ
) − ktr P rol
Circ

= ktr P rol − ktr T ransit1
= ktr T ransit1 − ktr T ransit2
= ktr T ransit2 − ktr T ransit3
= ktr T ransit3 − kcirc Circ

(5.2)

where P rol, T ransit1 , T ransit2 , T ransit3 and Circ denote the amount of neutrophil
count in the separate compartment. kprol , ktr and kcirc denote the proliferation rate, transit
rate and circulation rate. The drug effect E is expressed by Slope × Conc in our application. At steady state,

dP rol
dt

=

dCirc
dt

= 0, therefore, kprol = ktr = kcirc . Thus, the structure

model parameters are Circ0i , M T Ti , γi , andSlopei denoted by θiP D .
We assume that the variability of observed ANC reflects the inter-subject variation and
the measurement error expressed as,
yijP 0D |θiP D = fiP D (θiP D , θiP K , tij 0 ) + ηij

(5.3)

where f is a function of predicting ANC over time for subject i at time tij . The noise
errors are assumed to follow the normal distribution independently respectively.
ij ∼ N (0, σ12 )

ηij 0 ∼ N (0, σ22 )

(5.4)
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Given PK and PD model, the likelihood function is written as
p(yiP D , yiP K |·)

=

ni
Y

p(yijP D |θiP D , θiP K , tij 0 , σ22 )

j=1

ni
Y

p(yijP K |θiP K , tij , σ12 )

(5.5)

j=1

When we explored the data, we noticed that the shape of PD profiles are different and some
shared the similar shapes in the population. The different shapes of PD curves may suggest
investigate the heterogeneity of the population. Therefore, we proposed a nonparametric
Bayes prior which induces a clustering property. See the clustering property in chapter
4.1. The goal of using a DP is to link the individualized PK and PD model and cluster the
patients into groups. It helps us understand how drug works in the body.
(θiP D , θiP K )|G ∼ G
G ∼ DP (α, H)
H ≡ N (µ, Σ)

(5.6)

where α is the concentration parameter and H is the base distribution of DP. The final
stage includes additional hyper-parameters for σ 2 , µ and Σ, respectively.
σ 2 ∼ IG(a0 , b0 );

µ ∼ N (µ0 , Σ0 );

Σ ∼ IW (v0 , Σiw )

(5.7)

where IG denotes an inverse-gamma with mean b0 /(a0 −1), IW denotes an inverse-Wishart
distribution with mean Σiw /(v0 − p − 1), where p is number of parameters. The values of
a0 , b0 , v0 , Σiw , µ0 and Σ0 are fixed constants.

5.2

Euler Approximation

Using the differential equations is a common approach to describe a dynamic process in
practice. It is also widely used in PK and PD models as it provides a time-varying rate
of the response rather than the static average value. If the analytic solution of ODEs are
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available, we can obtain the solution from the existing packages given a starting value
of parameters. In practice, the analytical solution is often not available. For our case,
it does not have an exact solution. Thus we use a numerical default function, ode in R.
However, the simulation is pretty slow and the results are not stable either. We decided
to use Euler’s method to linearize the differential equations. Euler’s approximation make
the MCMC simulation 10 times faster than using the ODE solver in deSolve package. In
addition, the results are very stable too. In the end, we implement Euler’s method in the
PD model. Here we show more details of the implementation.
In PD model 5.3, the values of fiP D (·, tij 0 ) require the solution of a system of ODEs
given by 5.2. To keep the notations simple, we use the following equation to redefine the
differential equations.
dv
= g(t, v(t, θ i )) for
dt

t 6= t0

(5.8)

with v(t0 , θ) = v 0 (θ). The vector v(·) = (v1 (·), · · · , vq (·))T represents the dynamic
equations of q items, i.e. P rol, T ransit1, T ransit2, T ransit3, Circ in PD ODEs. v 0 (θ)
is an initial condition. g(·) = (g1 (·), · · · , gq (·))T is the known function with respect to
the parameters. The mean function fiP D (·) is directly related to v, i.e. f (·) = H(v(·), t)
where H is a known function.
We discretize the time points by an amount h, “step size”, which is the distance
between two consecutive time points. The observed time points may be unevenly distributed. We consider a discretization by N fixed time points t0 ≤ t1 ≤ t2 ≤ · · · ≤ tn
such that tk+1 − tk = h for k = 1, 2, · · · , (N − 1). We choose the maximal value for these
time points to be larger than tn so that we can obtain the approximately fitted response at
tn . The solution to the ODEs can be expressed as
Z

t

v(t, θ) =

g(s, v(s, θ))ds + v 0 (θ)
t0
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which approximately equals to
Z
v(t + h, θ) − v(t, θ) =

t+h

g(s, v(s, θ))ds ≈ hg(t, v(t, θ))

(5.10)

t

as h → 0. Let v˜k = ṽ(tk , θ) and µ˜k = µ̃(tk , θ) = H(v˜k ) for k = 1, 2, · · · ,. We can write
ṽ(tk+1 , θ) = ṽ(tk , θ) + (tk+1 − tk )g(tk , v(tk , θ))
µ̃k = H(ṽ k )

(5.11)

with initial condition v 0 (θ). If tk ≤ t < tk+1 , the value of approximate mean term at t is
given
µ̃(t, θ) = µ̃(tk , θ) +

t − tk
(µ̃(tk+1 , θ) − µ̃(tk , θ))
tk+1 − tk

(5.12)

Thus fiP D (·, tij ) is linearized by µ̃(t, θ) function. This method is known as “naive” Euler’s
method, µ˜h (t, θ) = µ̃(t, θ) + o(h). In our simulation study, we compare the Euler’s
approach with a regular integrator. The results show that Euler’s approximation improve
the simulation speed. However, we need to determine the optimal size of step size, h. In
addition, the optimal value of h is different across different patients. If h is too small, the
approximation process stops at a certain time point before reaching tN . In this case, we can
not find the correspondingly fitted response. It is not possible to compute the likelihood
function. If h is too large, we may have negative values which are meaningless in practice.
Therefore, we need to choose h carefully. See more alternative linearization approaches
such as “improved” Euler’s method or Runge-Kutta method in Ghosh et al. (2011).
We also addressed another issue in our MCMC simulation. In high-dimensional case,
it is difficult to optimize the tuning parameter to achieve efficient mixing. On one hand,
we hope the chain is able to explore more regions. On the other hand, we also hope
the proposed values are solvable in differential equations and are meaningful in practice.
Therefore we implement the adaptive Metropolis which can automatically “learn” better
parameter values of while the chain proceeds. We perform adaptive MCMC in both PK and
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PD model. The proposal distribution is given at iteration n by Qn (θ, ·) = N (θ, 0.12 Id /d
for n ≤ 2d; while for n > 2d,
2.382
Qn (θ, ·) = (1 − β)N (θ,
Σn ) + βN (θ, Σ0 )
d

(5.13)

where Σn is the covariance of empirical estimates θ1 , · · · , θn , d is the dimension of parameter space, β is a small number between 0 and 1. Σ0 is a fixed non-singular matrix which
keeps the covariance matrix from collapsing to 0, i.e. Σ0 = 0.12 Id /d. The proposal distribution, N(θ, 2.382 Σn /d), is optimal in a high-dimension situation, Robert et al. (1997) and
Roberts and Rosenthal (2001). In our work, we use a truncated sampling because some
candidates, such as negative or extreme values, are ineligible in PK-PD modeling setting.

5.3

Predictive inference

There are several beneficial properties using the nonparametric bayesian model. We are
able to tie the individual PK and PD model together and cluster the patients into several
groups. We can also make full use of the full time course of concentration information.
After performing the MCMC simulation, we are able to make inference of the clustering
distribution and estimate the parameters by borrowing the strength from other patients.
Additionally, we can do the prediction inference which is our greatest interest. We can
predict the new patients’ PD profile on the basis of their PK profile which is easier to
obtain in practice. We use Polya Urn scheme, see more details in chapter 4, Dirichlet process, to relate the new observation to the θ1? , θ2? , · · · at each iteration. Then the predictive
distribution of yn+1 is given by
Z Z
PD
PD
PK
PD PD
PK
p(yn+1 |y1:n , y1:n ) =
p(yn+1
|θn+1 , θn+1
)
PK
PD
PK
PD
PK PD PK
|θ1:n , θ1:n , yn+1
, y1:n
, y1:n
)
p(θn+1
, θn+1
PD PK PD
PK
PD
PK
p(θ1:n
, θ1:n |y1:n , y1:n
)dθ1:n
dθ1:n
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The middle term in equation 5.14 can be extended to
k

PD
PK
p(θn+1
, θn+1
|·)

nj X
α
PK PK
PK
∼
p(yn+1
|θj ) +
p(yjP K |θH
)
n + α j=1
n+α

(5.15)

where k is the unique number of components at each iteration, nj denotes the size of j th
PK
cluster, θH
is a random draw from the base measure H. See more results in the simulation

and real data studies.

5.4

Implementation of the MCMC Scheme to the PK/PD
model

In order to implement the sampling scheme clearly, we start out by simplifying the notations. Let θ? = c(θ1? , · · · , θk? ) denote the set of distinct θi s and k, (k ≤ n) is the number
of distinct elements. Let (c1 , · · · , cn ) denote the vector of configuration indicators, and
nj be the number of ci = j. We implement Gibbs sampling by iterative sampling ci from
the full conditionals. The subscript “−i” indicates without the ith element of the vector.
The superscript “−” refers to a summary with the appropriate observation or parameter
removed. For example, k − refers to the number of clusters formed by θ−i . n−
j represents
the number of elements in cluster j when observation i is removed. All these notations
work for both PK and PD.
The whole estimation sampling of mixture of DP model includes 4 steps. The first
step is the initialization. The second step is implement Gibbs sampling with auxiliary
components to sample the class configuration ci for i = 1, . . . , n. In third step, we use an
adaptive Metropolis algorithm to estimate θj? for cluster j. The last step is to specify the
hyper-parameters.
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Step 1: The initial state
The permanent chain consists of the class configuration ci , θipk and θipd . The initial values
for the class label are 1 to n. Solving differential equations requires a “good” starting
value to produce the reliable results. Thus, we set the initial values for θiP K and θiP D are
the maximum likelihood estimates for PK and PD respectively. The parameters in the
mixture model are initialized as follows. The base measure of DP, H, is a multivariate
normal with mean parameter, the mean of MLEs, and covariance matrix, the covariance of
MLEs. The precision parameter α is 1. The number of temporary auxiliary components
is 3. The hyper-parameters are set to: µpk = µpd = 0, ΣP0 K = ΣP0 D = Id , and inverseWishart with mean

Σiw
,
v0 −p−1

v0 = 6 (v0 > p + 1), Σiw = Id . a0 = 3 and b = 0.02 in the

inverse gamma distribution.

Step 2: Sample [ci |c−i , θ1:k− , θk− +1 , · · · , θk− +m ]
Repeatedly sample ci for i = 1, · · · , n from I to IV :

• I. If ci 6= cj for all j 6= i, then ci = k − + 1 and θkpk− +1 = θipk , θkpd− +1 = θipd . At the
same time, draw the other two auxiliary parameters, θkpk− +2 and θkpk− +3 independently
from H pk ; θkpd− +2 and θkpd− +3 independently from H pd .
• II. if ci = cj for some j 6= i, then ci = cj , θiP K = θjP K and θiP D = θjP D . The class
configurations for all auxiliary components are equal to k − + 1, k − + 2, k − + 3. The
three auxiliary parameters are randomly drawn from H pk and H pd .
• III. The corresponding probabilities in I and II are expressed as,

PK
PK
PD
PD
p(ci = c|c−i , yiP D , yiP K , θ1:k
− , θk − +1:k − +m , θ1:k − , θk − +1:k − +m ) ∝
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n−i,c p(yiP D |θcP D , θcP K , σ22 )p(yiP K |θcP K , σ12 )

for

1 ≤ c ≤ k−,


 α p(y P D |θP D

for

k− < c ≤ k− + m

m

i

PK
2
PK PK
|θau , σ12 )
auxiliary , θauxiliary , σ2 )p(yi

• IV . After renewing each ci for i = 1, . . . , n, discard θpk and θpd which are not
associated with any observations, y1 , · · · , yn . Keep the permanent terms, ci , θipk and
θipd for i = 1, · · · , n.
In order to keep the notation simple in the following steps, let θ1pk,? , · · · , θkpk,? denote the
pd,?
distinct values of θ1pk , · · · , θnpk , similar for PD, and θ1:k
. The unique values of the class

configuration is expressed as c?1 , · · · , c?k .

?
?
Step 3: Sample [θpk
|yi , ci = k] and [θpd
|yi , ci = k]

In our model, we consider that θ1pk,? , · · · , θkpk,? are i.i.d from N (µpk , Σpk ). Where µpk ∼
pk
pk
N (µpk
∼ Inverse-Whishart(v0 , Σpk
0 = 0, Σ0 = Id ) and Σ
iw ). Since these are conjugate
pk,?
pk,?
priors, we can compute the full conditional distribution of µpk |θ1:k
, Σpk and Σpk |θ1:k
, µpk .
PT pk
pk
1:T
We used Gibbs sampler to sample (µ1:T
pk , Σpk ) T times and set µpost = (1/T )
1 µi and
P
T
pk
Σpk
post = (1/T )
i=1 Σi . See more details in chapter 4 section 2. It is similar for PD part
pk
pk
pd
(µpk
post , Σpost ). We have K clusters after step 2, then we update θk and θk in the following

steps.
pk
Repeat I and II for k = 1, . . . , K. We take k th cluster as example. Sampling θkpk |yi∈k

is as follows,
• I. The posterior distribution (target) is proportional to
p(θpk |yipk , ci = k) ∝

Y

p(yipk |θkpk )π(θkpk )

(5.16)

i∈k

Since there is no close form of likelihood, we use Metropolis-Hastings algorithms
with an optimal proposal and an adaptive Metropolis algorithm in MCMC simula-
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tion. Propose a candidate, θ˜pk from 5.13 where θ is the current value of θipk and Σn is
the covariance of all the unique estimates in the previous states. The final acceptance
rate is,
(
α(θpk , θ˜pk ) = min 1,

Q
Q

pk pk
pk
i∈k p(yi |θ̃ )π(θ̃ , µpost , Σpost )
i∈k

)

p(yipk |θkpk )π(θkpk , µpost , Σpost )

If the proposed values is accepted, we set θk = θ̃; otherwise, keep the current one.
pd
pk
• II. The steps of sampling θkpk |yi∈k
, yi∈k
, θkpk are the same as (3I) except the target

density. It becomes,
pd
pk
p(θkpd |yi∈k
, yi∈k
, θkpk ) ∝

Y

p(yipd |θkpd , θkpk )

i∈k

Y

D
D
p(yipk |θkpd )π(θkpk , µPpost
, ΣPpost
)

i∈k

Step 4. Re-sampling the hyper-parameters in the model
The typical mixture of Dirichlet process applications would include the hyper-priors. In
each iteration, we do update the prior information given the associated observations are
observed. For example, we update µpk and Σpk after we have the random sample θ1pk , · · · ,
θkpk . It is same as for µpd and Σpd too. In addition, we also update σ12 and σ22 given
the Markov chain estimates in each iteration. We assume that the pk response yijpk ∼
N (fipk (θipk , tij ), σ12 ) and σ12 ∼ gamma−1 (a0 , b0 ). Given all the observations yij , for i =
1, . . . , n and j = 1, . . . , ni , the posterior distribution of σ12 |yij can be expressed as,
pk

pk

p(v|y , θ ) ∝

ni
n Y
Y

p(yijpk |v)π(v)

i=1 j=1

2


1 N
∝ ( ) 2 +a0 −1 exp−
v

1/2

P P
i j

yij −f

pk pk
(θ ,tij )
i
i

+b0

v

where v ≡ σ 2 . Therefore σ 2 |y ∼ gamma−1 ( N2 + a0 , 12

PP
(yij − fijpk ))2 + b0 ). Similarly,

we can sampling PD parameters from the posterior distributions. We update σ12 and σ22 at
each iteration.
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Repeat step 2, 3 and 4 to obtain a desired number of MCMC runs. There are more
inference results in the simulation as well as real data.

5.5

A simulation study

In this section, we evaluated our proposed approach in a simulation. The simulation data
is based on the real clinical trial study. We generated both PK and PD data for 30 patients.
The “true” values of parameters are the maximum likelihood estimates of 3 patients who
have different shapes of PK and PD profiles in the real data Figure 6.2. The noise were
added, i.e. N(0, 0.01) for PK and N(0, 1) for PD, respectively. The variance is adopted
to prevent the responses to be negative or too close to 0. We kept the well-balanced and
non-negative response values.
The system of nonlinear differential equations do not have an exact solution. We used
deSolve, a R package, to solve the ODEs at first. However, it is slow and the results are
unstable due to the complex structure of ODE system. A MCMC simulation with 1000
iterations were tested using one of most popular numerical solver of ODEs in deSolve
package. On average, it takes more than 6 minutes to complete an iteration. To compare,
Euler’s method was tested under the same setting. It took 0.63 minute for one iteration.
Thus Euler’s approach is almost 10 times faster than lsoda solver. Figure 6.3 and 6.4 show
that the mean of PD parameter estimates with 95% probability interval. Each column represents the parameter mean estimates for one patient. The estimates for both approaches
are very close to each other for each patient. As ODEs were needed to solve more than
1000 times in each iteration, Euler’s method was adopted for the following MCMC simulation. Moreover, we implement a combination of Metropolis-Hastings algorithm and a
Gibbs sampling with auxiliary components in the MCMC simulation. See more details
about MCMC algorithm in chapter 5, section 4.
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Figure 6.5 shows the distribution of the clustering distribution of the maximum likelihood estimates. Our approach indicates that there are 3 groups among 30 patients because
it has a relative large weight. This result is consistent to the true setting. Figure 6.4 predict
the individual parameter estimate with 95% probability interval. We can see that the first
ten patients’ parameter estimation as well as the confidence interval are very close to each
other. It suggests the first 10 patients belong to a cluster. Similarly, the last 10 patients
should go into second group. The rest belongs to the third cluster. At the same time, PK
parameter estimates show the similar pattern too, Figure 6.6. The Dirichlet Process is best
used for density estimation, and, as it is our case, for borrowing strength across observations and improving estimation when the curves need to be estimated with sparse data.
This appears to be overall achieved by our model.
Our approach with Euler approximation can improve the estimates across the cycles.
Figure 6.7 shows three PD curves fitted with an ODE solver package in R, and the “true
curve” that are used to generate the data as well as the final simulated data points (cross
signs). Figure 6.8 present the PD curves with Euler’s estimates for three patients in the
simulation data. The fitted values are estimated by fiP D (t) = (θ̂ipd , t), where θ̂i is the
posterior mean from MCMC samples.
Figure 6.9 shows that the PD response for a new patient are estimated by fˆP D (t) =
P P D pd
1/T
f (θn+1 , t), where θit is the t-th imputed parameter vector θi in simulated Monte
Carlo posterior sample. The interval is 95% probability interval of the predicted response
PK PK
PK
for each observed time point. In each iteration, we use p(yn+1
|θ1:n , θauxiliary
, σ1 ) to de-

termine the new patient going into which clusters. If the new patient goes into “true”
cluster which are used to generate the new patient data, the curve will be completely consistent with the data. However, it is possible that the new patient will be assigned in one of
two existing clusters or the new cluster. In this case, the predicted curve will be not consistent with the data as we expected. The final predictive distribution might heavily depend
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on the cluster assignment in the estimation step. The mean response at each observed data
point is an average value of all predictions from different cluster across iterations. For a
new patient generated from ID 57 occasion 1, there is 86.4% iteration that our model assigns the new patient to the “true” curve, 1.4% iteration that the new patient goes into the
new cluster, 7.2% iteration that it is assigned to the first cluster which generating the first
ten cycles, 28.4% iteration that it goes to the second cluster which simulates the middle
ten cycles. See results in Figure 6.9.
In addition, we check the trace plot of a patient’s PD parameters, Figure 6.10. The plat
line (“gap”) in the plot indicates that the proposed candidates is meaningless so we keep
the current state values.

5.6

Real data example

Here we use a real clinical trail data, Friberg (2002), to assess the performance of our
proposed approach. Usually, the clinical data has a precise administration. Overall 45
patients with different cancer forms only received paclitaxel, a single anticancer agent in
196 cycles (varying between one and 18 cycles per patient, median, 3 cycles). Paclitaxel
was administered as a 3-hour infusion, with an initial dose of 175 mg/m2 every 3rd week.
Unbound plasma concentrations were monitored on course 1 and course 3, with an average
of 3.5 samples per patient and course.
We chose 40 cycles from 45 patients. These 40 cycles satisfy two conditions. First, the
cycle has PK and PD data. Second, PD cycle has three or more observations. Figure 6.11
shows two fitted curves in the real data. The parameter initialization is the same as those
in the simulation study. The following estimation and prediction results are based on 5000
MCMC simulation.
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Figure 6.12 shows that the PD response for a new patient are estimated by fˆP D (t) =
P
1/T Tt=1 f P D (θpd,t ), where θpd,t is the t-th imputed parameter vector in simulated Monte
Carlo posterior sample. The interval is 95% probability interval of the predicted response
for the observed time point.
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We provide a coherent probability model for the analysis of PK/PD mechanistic model. By
using a bayes approach, we are able to tie individualized PK and PD cycles together, obtain
the inference on patients’ clustering on the basis of their concentration or response profiles. The cluster configuration allows us to predict the new patients’ drug response based
on its drug concentration data set. This approach helps us to investigate the heterogeneity of the population and then provides us a chance to gain more information from each
subpopulation. This model not only can combine prior information with the clinical trial
data, but also deal with complex dynamic systems. Thus the results of estimated dynamic
parameter based on this model should be reliable and reasonable to interpret long-term
PK/PD dynamics. This approach can help us better understand how the drugs work in the
body first in the subpopulation then in the whole population.
Although nonparametric Bayesian model is a promising perspective to address the
population PK/PD models, there are several challenges too. First, our approach is highly
computationally intensive. Our model requires solving a system of nonlinear differential
equations. It becomes very difficult when we have a limited data in a few cycles. That is
also one of the reasons that we introduced the Euler’s method to approximately estimate
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the corresponding response. Another challenge is that how to set up a reasonable truncated
the proposal distribution so that we can allows the chain to explore a large region and also
propose the doable parameters which is solvable in the highly unstable ODEs system.
More importantly, the proposed values are physiologically meaningful.
There are two directions I am interested in the future. One is to improve our approach
by incorporating the available covariates information including body surface area, bilirubin (hematoidin, excreted in bile), genetic biomarkers as well as the basic demographic
variables. The second direction is about missing data. We want to provide a reasonable
approach to deal with the “missing” data since it is a fairly common issue in clinical trial.
In real example, we only have one or two data points for some PD cycles. We are not very
clear how to do the parameter estimation. Right now, many software packages either throw
away all subjects who have missing data or impute missing values with population mean
or some fixed values. The first approach throws away a potential large amount information, where as Hoff et al.(2009) proposed to use Gibbs sampling for the missing data.
Tsiatis et al.(2006) discussed the nonparametric theory and missing data which provides
us the framework to do deep research. In addition, we plan to write a R package for our
approach.
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Figure 6.1: Neutrophil cell proliferation model with feedback. Stem or progenitor cell
compartment, Prol; Maturation compartment for transit including Transit 1, Transit 2,
Transit 3. circulating neutrophil compartment, Circ. Edrug represents drug effect. Feedback represents the strength of rebound cells. M T T measures the mean transit time. kprol ,
ktr and kcirc represent the proliferation rate, transit rate and circulation rate, respectively.
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Figure 6.2: The fitted curves chosen for generating the simulation data.
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PD posterior mean with 95% CI
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Figure 6.3: PD parameter estimates: posterior mean with 95% probability interval across
patients using Euler linearization.
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Figure 6.4: PD parameter estimates: posterior mean with 95% probability interval across
patients using lsoda solver.
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Figure 6.6: PK parameter estimates: posterior mean with 95% probability interval across
patients.
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Figure 6.7: Fitted curves with MLEs for three patients in the simulation study.
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Figure 6.8: Fitted curves with posterior mean for three patients in the simulation study.
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Response prediction with 95% CI, ID 57 OCC 1
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Figure 6.9: Predicted absolute neutrophil count for a new patient in the simulation study.
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Figure 6.10: Trace plot of PD parameters across the iterations.
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Predicted ANC and 95% probability inverval for a new patient with ID 62
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Figure 6.12: Predicted absolute neutrophil count for a new patient in the real data.
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